




Title of Dissertation:  MULTIPLE ANTIBIOTIC RESISTANCES OF ENTEROCOCCI  
 
FROM THE POULTRY PRODUCTION ENVIRONMENT AND  
 




PHENOTYPES OF ENTEROCOCCUS FAECIUM  
 
Joshua Richard Hayes, Doctor of Philosophy, 2004 
 
 
Dissertation directed by: Sam W. Joseph, Professor 




 Enterococcus spp. were collected from poultry production and processing 
environments across a region of the eastern seaboard of the United States.  Using a 
microtiter plate adaptation of traditional biochemical assays, 532 isolates were identified 
to the species level.  E. faecalis was observed to be the predominant species recovered 
(64%), followed by E. faecium (24%), E. hirae (6%), E. gallinarum (5%), and less than 
1% of E. avium, E. casseliflavus, E. durans, and indeterminate species.  All isolates were 
tested for susceptibility to 28 antimicrobials using broth microdilution.  Antimicrobial 
resistance was observed among the isolates with E. faecalis more resistant to 
lincosamide, macrolide, and tetracycline antimicrobials and E. faecium more resistant to 
fluoroquinolone and penicillin antimicrobials.  Resistance to multiple antimicrobials was 
observed among all species, with a proportionately greater diversity of resistance 
phenotypes among isolates of E. faecium.  The prevalence of resistance to an important 
antimicrobial used in human medicine, the streptogramin quinupristin-dalfopristin, was 
demonstrated among 63% of E. faecium isolates.  These observations led to the 
investigation of the molecular determinants among those isolates of E. faecium that 
contributed to resistance to the group of antibiotics known as the macrolide-lincosamide-
streptogramin (MLS) superfamily.  Ribotype analysis demonstrated that four ribotypes 
constituted 65% of the observed population, but displayed diverse antibiograms, 
suggestive of the acquisition of multiple resistance elements to other antimicrobials.  This 
was consistent with the absence of geographic clustering of MLS phenotypes or 
ribotypes.  Colony PCR screening for the streptogramin resistance determinants erm(A), 
erm(B), mef(A), lnu(B), msr(C), vgb(A), vat(D), and vat(E) was performed.  Resistance 
to streptogramin antimicrobials was largely unaccounted for by PCR screening for 
specific resistance determinants.  Erythromycin methyltransferase determinants erm(A) 
and erm(B) were observed among 7.5% and 5% of resistant isolates whereas the efflux 
gene msr(C), the streptogramin B hydrolase vgb(A), or the streptogramin A 
acetyltransferase genes vat(D) and vat(E) were not detected among resistant E. faecium.  
Mef(A) was detected in only 4% of macrolide-resistant isolates whereas the screening for 
lnu(B) was not successful.  These results indicate that streptogramin resistance is 
widespread among E. faecium from the poultry production environment but the 
mechanisms of resistance within this population remain largely uncharacterized.   
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 Microorganisms have a dynamic relationship with the biosphere after continually 
adapting to inconstant environmental conditions, thus generating an enormous amount of 
genetic diversity.  The ecological niches that these forms of life occupy are limited and 
are under ferocious competition.  Advances in the understanding of microbial ecology 
have only relatively recently allowed scientists to consider the bodies of many animals as 
rich harbors for many forms of life.  Bacteria that inhabit animal niches can colonize and 
proliferate on or within a host and establish a similarly vigorous association.  This 
relationship with the individual can range from beneficial to outright deadly.  One 
particularly interesting common group of inhabitants of this environment is the genus of 
gram-positive cocci, Enterococcus. 
 
Genus Description 
 Members of the genus Enterococcus, first described in 1899 by Thiercelin (289), 
are gram-positive, catalase negative, cocci that occur singly, in pairs, or short chains.  
Enterococci are homofermentative lactic acid bacteria that are facultatively anaerobic and 
can grow between 10 and 45oC, with optimum growth in most species at 35oC.  All 
known members of the genus grow in broth containing 6.5% NaCl and hydrolyze esculin 
in the presence of 40% bile salts.  Most described species hydrolyze pyrrolidonyl-β-
naphthylamide (PYR), whereas only two species are motile.  Enterococci can be α, β, or 
γ-hemolytic on blood agar.  Twenty-six species have been proposed since the removal of 
S. faecalis and S. faecium from the genus Streptococcus to form the genus Enterococcus 
(Table 1)(256).   
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Ecological Distribution 
Enterococci are considered important members of the intestinal microflora of 
mammals, reptiles, birds, fish, and insects as well as in plant environments 
(27,68,70,94,203).  Members of Enterococcus spp. can also be found in the soil, water, 
and food (77,152,202,204).   
More specifically, E. avium, E. durans, E. faecalis, E. faecium are frequently 
isolated from cheese products (26,110,174) whereas E. avium, E. casseliflavus, E. 
durans, E. faecalis, E. faecium, E. gallinarum, and E. hirae have been described 
components of the microflora of various raw meat products (72,123,288).  It is important 
to note that members of these species are frequently employed as starter cultures in 
fermented food products.  The high prevalence of these species in raw meat is closely 
related to the fecal microflora from the food animal species (69,70,121,196,288,313).  
Despite the presence of enterococci in 82-100% of retail meat products (123,186), studies 
of cooked meat suggest that enterococci do not constitute the largest population on such 
products (19).   
Although the enterococcal population within the human intestinal tract does not 
account for more than 1% of the total microflora, the population is quite diverse (262).  
Enterococcus faecalis and E. faecium, in particular, are by far the most prevalent species 
found (89,187).  E. casseliflavus, E. durans, E. gallinarum, E. hirae also contribute 
significantly to the enterococcal fecal microflora of humans (165,197,266) whereas E. 
avium and E. mundtii have only been occasionally isolated (105,278).   
Enterococci that have been isolated from domesticated pets include E. avium, E. 
durans, E. faecalis, E. faecium, and E. hirae (68).  E. avium, E. casseliflavus, E. durans, 
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E. faecalis, E. faecium, E. gallinarum, E. hirae, and E. mundtii have been isolated from 
surface waters (121,238,283,297) whereas only E. hirae has been identified from 
groundwater (49).  E. casseliflavus, E. faecalis, E. faecium, and E. sulfureus have also 
been associated with plant materials (201,222,305).   
 Among the more rarely isolated species, E. cecorum has been isolated from 
domesticated pets (68) and feces from bovine and poultry sources (69,70).  E. dispar has 
been isolated from poultry feces (221).  Since its initial isolation from Gouda cheese (55), 
E. malodoratus has been isolated from poultry feces (221) and has been associated with 
spoilage of sausage (162).  Although primarily associated with soil and plant material, E. 
mundtii has been isolated from fish and meat products (57,72,227).  E. mundtii has also 
been identified as components of the intestinal microflora of chickens (69).  E. 
pseudoavium has been isolated from pigs and poultry (162,221).  E. raffinosus has rarely 
been isolated outside of the clinical environment, but has been identified from domestic 
pets (68).  E. sulfureus has been isolated only from grass and fish sources (201,222). 
E. solitarius and E. seriolicida have been reclassified as members of the genera 
Tetragenococcus and Lactococcus, respectively.  Recently, two new proposed species of 
pigmented enterococci, E. gilvus and E. pallens, were described from clinical isolates 
(293).  These species, in addition to E. asini, E. canis, E. haemoperoxidus, E. 
moraviensis, E. phoeniculicola, E. porcinus, E. ratti, and E. villorum, are recent additions 
to the genus and their distributions in different environments are unknown.   
 It is worth noting that reports of the ecological distribution of Enterococcus spp. 
in different environments may be hard to compare due to differences in isolation 
methodology.  Most surveys to date have been focused on the isolation of what are 
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thought to be the most abundant species of enterococci, i.e., heavily influenced by those 
studies conducted in clinical settings.  Recent changes in the taxonomy of enterococci has 
revealed that an ever-increasing number of species do not conform to long-held 
descriptions of the genus.  For example, not until the description of the PYR-negative 
species of E. cecorum, E. columbae, and E. saccharolyticus has the PYR reaction been 
used other than as a definitive characteristic of Enterococcus spp.  Other factors that 
might influence the recovery and/or prevalence of non-dominant species include the 
choice of media, the temperature of incubation, composition of the incubation 
atmosphere, and identification methodology (39,215,322).  Given the close similarity of 
the newly described species to long-standing members of the genus, confident 
identification to the species level may not always be possible using traditional 
biochemical testing (71). 
 
Pathogenicity 
Whereas enterococci are thought to account for no more than 1% of the adult 
intestinal microflora, the medical importance of enterococci outweighs their relative 
abundance (262).  Of the 26 species that have been proposed to belong to the genus, only 
11 (E. avium, E. casseliflavus, E. durans, E. dispar, E. faecalis, E. faecium, E. 
gallinarum, E. hirae, E. mundtii, E. pseudoavium, and E. raffinosus) have been described 
as associated with human disease (205).  E. faecalis accounts for 80-90% of enterococcal 
isolates of clinical origin, with E. faecium the second most prevalent enterococcal 
species.  Despite the lower frequency of isolation from clinical settings, E. faecium 
isolates are disparately resistant to treatment with antimicrobial chemotherapy (84). 
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Although normally commensal in nature, enterococci are responsible for 
approximately 10% of urinary tract infections and 16% of nosocomial urinary tract 
infections (96,253).  They are also commonly isolated from wound infections of the 
abdominal area (151) as well as those from crushing injuries (64).  Enterococcal 
bacteremia is the third leading cause of nosocomial bacteremia (114) with an estimated 
fatality rate of 28 to 58% (180).  Enterococci are also responsible for between 5 and 20% 
of cases of bacterial endocarditis (188).  Enterococci have been described as one of the 
most destructive agents that cause postoperative complications of cataract surgery (119). 
Up to 13% of bacteriologically confirmed cases of neonatal sepsis have been attributed to 
enterococci (24).  Those who are elderly or have an underlying compromising situation 
are predisposed to enterococcal infection, especially in the hospital environment (205).  
This is a significant observation given the ability of enterococci to colonize surfaces of 
the hospital environment (333) and persist on fingertips and dry surfaces (217).  As a 
result, enterococci seeding the clinical environment may be more easily spread if 
infection control measures are poorly implemented. 
 
Virulence Factors 
 In addition to the hardiness of the genus, other components have been implicated 
as important factors in the sequence of events that lead to clinical human disease.  Acid 
tolerance, mediated by any stimulus that causes an increase in proton pump activity, is 
thought to allow enterococci to survive passage through the stomach prior to colonization 
of the lower bowel (101,282), although it remains to be seen whether this mechanism is 
enhanced among isolates responsible for nosocomial infection.  Aggregation substance is 
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thought to play a role in the translocation of enterococci from the intestinal lumen to the 
mesenteric lymph nodes, liver, and spleen (312) although additional mechanisms are 
thought to also contribute (220).   
Another factor thought to be involved in adhesion is enterococcal surface protein 
(Esp), which has also been demonstrated to aid in the formation of a bacterial biofilm 
(291) and contributes to a mouse model of urinary tract infection (264).  The pheromone-
responsive β-hemolysin, known as cytolysin, has been shown to decrease the lethal dose 
of bacteria in animal models, although its mode of action in disease is unknown (191).  
The production of the secreted zinc metalloprotease, gelatinase, is also thought to play a 
role in systemic disease (76), perhaps through the modulation of the host immune 
response (251).  An enterococcal adhesin, Ace, which mediates binding to extracellular 
matrix proteins, has recently been identified as a potential virulence factor that may 
contribute to enterococcal endocarditis (210,211,239).  A similar collagen-binding 
adhesin, Acm, has also been described among clinical isolates (212).  It is thus likely that 
different sets of these determinants contribute to the colonization and virulence 
depending upon the infection site. 
 Whereas typically considered to be an important member of the commensal flora 
that help to produce vitamins and convert toxic metabolites as well as maintain the 
structure and function of the intestinal epithelium, recent evidence has suggested that 





Prevalence of Virulence Genes 
 Nearly 50% of E. faecalis isolates from food sources possessed the asa1 gene, 
which encodes the aggregation substance (104).  The prevalence of this gene among E. 
faecalis isolated from endocarditis infection has been observed at 26% of isolates and has 
also been detected among 18% of E. faecalis isolates from well-water (25).  Asa1 was 
observed in 64% of fecal isolates from healthy subjects whereas 32 to 40% among 
clinical isolates possessed the gene (131).  In contrast to the observed prevalence of 63% 
among clinical isolates of E. faecalis from Germany, only 13% of E. faecium isolates 
possessed asa1 (86).  In contrast, other studies have not observed the presence of this 
gene among E. faecium from multiple environments (81,104,181). 
The prevalence of the enterococcal surface protein gene esp ranges from 32 to 
44% among E. faecalis and 68 to 78% of E. faecium of clinical origin (53,81,181,306).  
This is in contrast to prevalence rates of 36% of E. faecalis and a single E. faecium 
isolate from food sources (104).  The gene is infrequently observed in isolates of E. 
faecium outside of the clinical environment (104,181).   
The prevalence of cytolysin has been estimated between 11 to 56% of E. faecalis 
isolates of clinical origin, whereas it was not detected among isolates of E. faecium 
(81,86,306).  Whereas this trait has been found in 17% of E. faecalis isolates from feces 
from healthy Japanese subjects, up to 60% of those of clinical origin were found to be 
hemolysin producers (133).  It has also observed in 21% of E. faecalis and 8% of E. 
faecium from a variety of food sources (104). 
Gelatinase, encoded by the gene gelE, was observed among 27 to 68% of clinical 
E. faecalis isolates (58,86,306).  Up to 91% of clinical E. faecalis isolates may harbor 
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gelE (81,232), but only express the gelatinase-positive phenotype in the presence of a 
regulatory locus (232).  Gelatinase activity has been observed in 49% of food isolates of 
E. faecalis (104).  Most studies have not detected gelE among isolates of E. faecium from 
various environments (58,86,104,306) although in a single study gelE was observed in a 
single clinical isolate in the absence of gelatinase activity (81). 
The ace gene has not been detected in any species other than E. faecalis, 
suggesting that the gene is specific only to this species (75).  Another adhesin gene, acm, 
has been similarly described among clinical isolates of E. faecium (212).  No 
observations of successful conjugative transfer of either the ace or acm genes have been 
reported.   
Clinical strains of E. faecalis have been shown to be comparatively enriched in 
virulence determinants with the observation of regions of the enterococcal genome that 
apparently serve as a pathogenicity island (81,263).  The combination of multiple 
virulence factors within clinical E. faecalis in a subsequent study did not demonstrate 
such a strong association or an association of virulence factors and mortality (306). 
Conjugative transfer of certain virulence determinants between strains of E. 
faecalis has been well documented (52).  Aggregation substance-encoding genetic 
determinants have been transferred in situ from a clinical isolate of E. faecalis to one 
used in cheese and sausage fermentation and remained a stable trait in these 
environments (53).  The transfer of virulence determinants from clinical isolates to starter 




Clinical Antimicrobial Resistance 
The introduction of the newest generation of antibiotics, penicillin in 1944 
(48,102) and streptomycin in 1945(255), was thought to preface the demise of infectious 
diseases.  As early as 1940, however, enzymes responsible for antibiotic resistance had 
been described from laboratory studies of resistance in staphylococci (154), pneumococci 
(257), and E. coli (8,9,207).  The subsequent appearance of resistant bacteria among 
clinical bacterial isolates was recognized as an increasingly familiar trend (80,100).  
Investigations of multiply resistant Salmonella (65) and Shigella (155) isolates from 
epidemics demonstrated that antimicrobial resistance could be spread among other enteric 
bacteria (307).  These observations were the first to suggest that the use of antimicrobials 
would be accompanied by antimicrobial resistance presenting a widespread challenge to 
the treatment of human bacterial infections. 
Multiple-drug resistant (MDR) enterococci have been on the rise for the past two 
decades.  High-level gentamicin resistance was reported in 1979 (130) and was followed 
by the emergence of a serious pathogen in the nosocomial environment in the 1980s 
(330).  With the emergence of penicillin-resistant enterococci due to the acquisition of a 
β-lactamase in the early 1980s, the drug of choice to treat MDR enterococci has been the 
glycopeptide, vancomycin.  Resistance to this vanguard of antimicrobial treatment 
emerged first in Europe in 1986 (295), followed by emergence in the U.S. in 1989 (249).   
Vancomycin-resistant enterococci (VRE) infections in the U.S. have increased 
twenty fold from 1989 to 1993 (43).  Increases in the incidence or detection of VRE 
worried some that the “post-antimicrobial era” was imminent, due to fears that the 
elements responsible for resistance would be transferred to staphylococci (54).  
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Vancomycin resistance has been transferred via conjugation in the laboratory from 
Enterococcus to the more virulent Staphylococcus aureus, rendering them untreatable 
(216).  This fear has recently been documented in the clinical environment, however the 
prevalence of vancomycin-resistant S. aureus is thought to be relatively low (45,46).    
Studies show that the risk of death resulting from bacteremia caused by a 
vancomycin-resistant Enterococcus isolate is several fold higher than that with 
bacteremia due to a susceptible isolate (83).  Patients that develop resistant infections can 
continue to carry VRE in feces for up to two years and provide a source for 
environmental dissemination (243).  In addition, resistant bacterial infections, in general, 
represent a financial burden, as the estimated cost of extended in-hospital stay in the U.S. 
caused by six different bacteria including VRE is at least $1.3 billion per year (219) and 
total cost may exceed $4 billion per year (12). 
 
Agricultural Antimicrobial Resistance 
 The origin and spread of bacterial resistance is currently an incomplete and 
contentious issue.  In the case of VRE, resistance was first recognized among isolates of 
E. faecium recovered outside of health care settings in 1993 from sewage treatment plants 
in urban areas of England (23) and in small towns of Germany (159). The relationship of 
this troubling human pathogen to agriculture was first made when VRE were cultured 
from the farm in 1994 from livestock feces and from uncooked chicken purchased at 
retail outlets in the UK (22).  The impact of agricultural use of antimicrobials, 
specifically the glycopeptide avoparcin, was suggested when VRE were found in fecal 
samples of German pigs and poultry (158).  The similarity between vancomycin and 
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avoparcin was extended past the structural level with studies that have established that 
the use of avoparcin at subtherapeutic levels for growth promotion in agriculture selects 
for VRE (1,3). 
Producers use antimicrobials at low or “subtherapeutic” doses because they 
promote faster animal growth on less feed.  The discovery of the effect of antimicrobial 
agents on animal growth was first suggested in 1946 by a team of scientists working with 
poultry (199).  By 1950, research reports had appeared in several journals claiming to 
document the benefits of subtherapeutic doses of tetracyclines and penicillins in other 
systems including swine (63) and calves (173).  The current understanding of the 
Antibiotic Growth Effect centers on the similar growth characteristics and feed efficiency 
of antibiotic treated and germ-free animals (146).  Antimicrobial-assisted growth is 
largely thought to arise from the reduction in numbers of total bacteria, which reduces 
normal inflammation of the tissue, thus providing a larger surface area over which 
nutrients can be absorbed. 
Due to the small profit margins involved in poultry production and the vertical 
integration of the industry, producers have been reluctant to remove antimicrobials from 
poultry diets.  As many as thirty thousand birds are raised in a poultry house and are 
subjected to a variety of environmental stresses, including temperature extremes, 
malfunctioning water equipment, or improperly mixed feed.  These conditions, if 
persistent, can and do result in significant mortality among the flock.  It is the opinion of 
the National Research Council that the “beneficial effects of subtherapeutic drug use are 
found to be greatest in poor sanitary conditions” (214).  Thus, recent advances in 
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agricultural production, designed to maximally increase product and profit, have grown 
to rely heavily upon antimicrobial agents. 
The consequences to human health of using antimicrobials in food have been 
difficult to delineate, but evidence is mounting that the use of antimicrobials for growth 
promotion may compromise use of either those or related antimicrobials in human 
therapy.  Dating back to 1965, when an outbreak of drug resistant Salmonella in England 
in dairy calves that eventually spread to humans, there have been continuing concerns 
over the use of human therapeutics as growth promotants.  This incident led to the 
formation of the Swann Committee to examine the use of antibacterial agents in England.  
The Committee recommended in 1969 the removal of antibacterial agents and antibiotics 
used for growth promotion from agriculture or the division of the antimicrobials into 
“feed” and “therapeutic” classes in order to more strictly control the use of antibacterial 
agents (284).   
More recently, Smith et al. (272) documented the rapid rise (1 to 10 percent) in 
fluoroquinolone-resistant Campylobacter jejuni isolates from Minnesota following the 
1995 approval of fluoroquinolones for use in poultry.  This finding, in part, led the FDA 
to announce its intention to withdraw approval of the use of fluoroquinolones in poultry.  
In the U.S., a case of salmonellosis in a Nebraska boy caused by a ceftriaxone-resistant 
isolate of the multiresistant bacterium Salmonella enterica serotype Typhimurium DT104 
was linked to an identical strain on a neighboring farm, but the evidence of transmission 
was circumstantial (99).  Another outbreak of S. enterica serotype Typhimurium DT104 
in humans was traced back to a swine herd infected with the same strain of bacterium, 
presumably the result of selection on the farm from the use of a fluoroquinolone growth 
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promoter (195).  According to Dr. Abigail Salyers, the study is the “closest that anyone 
has come to a smoking gun” linking agricultural use of drugs to antimicrobial resistance 
that contributed to a particular human death (97). 
Concern over possibly compromising the tools for efficacious antimicrobial 
human therapy by continuous use in agriculture led to the 1998 ban on the use of four 
growth promotants in the European Union.  The World Health Organization subsequently 
recommended in 2000 the banning of antimicrobials important for human medicine from 
use as growth promoters in animals (328).  These official actions, however, have relied 
upon the “Precautionary Principle” in seeking to prevent the increased prevalence of a 
hazard before that hazard has been scientifically established (230). 
 Whereas the routes of transmission of VRE have not been clearly identified, work 
in the EU has demonstrated human fecal carriage in the community (113,260,304) and 
that the vector may be the consumption of contaminated meat (260).  To date, insufficient 
evidence is available to conclude if this situation is mirrored in the U.S., due to the 
apparent complete absence of VRE in the community.  This is thought to be due to the 
absence of selective pressure in agriculture, as avoparcin was never approved for 
production purposes in the U.S.  This effect has also been mirrored in the observations 
that followed the 1986 ban of the use of any antimicrobial as a growth promotant in food 
animals by Sweden (298,301).  A critical difference between the EU and U.S. situations 
is the apparent overuse of vancomycin in U.S. hospitals (88,285) which is thought to 
amplify the size of the VRE populations which then can spread clonally within the 
hospital.  Thus, the impact of antimicrobial agents used in the production of food animals 
is thought to increase carriage in the community (e.g., in the EU) with an intense 
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secondary selective pressure at the hospital setting (e.g., in the U.S.) that can then lead to 
disease due to VRE or to seed the nosocomial environment, through which it can 
disseminate (185).  In fact, the use of vancomycin in a hospital setting is considered a risk 
factor for human VRE infection (83,265). 
One extremely important limiting factor in the estimation of the risk to human 
health poised by the agricultural usage of antimicrobial agents is the availability of usage 
data of antibiotics in the U.S.  Traditionally, drug companies are reluctant to release 
information regarding antibiotic use for fear of losing “proprietary” information.  Reports 
from trade groups such as the Animal Health Institute use the estimate of 50 million 
pounds of antibiotic produced in the U.S. per year as the measure for total production of 
antibiotics in the U.S., of which 36% are used in animals for therapeutic and non-
therapeutic purposes, compared with 64% for human treatment (13).  A recent report by 
the Union of Concerned Scientists asserts that 70% of antimicrobials are used in the non-
therapeutic treatment of food animals (294), suggesting that antimicrobial usage in 
animals for growth promotion is much greater than previously believed.  Representatives 
of U.S. agriculture as well as the pharmaceutical industry continue to vigorously defend 
the use of antimicrobials in agriculture against claims of compromising the treatment of 
clinical disease. 
 
Enterococcus as a Model for Resistance Development 
 In addition to the widespread distribution of enterococci in the environment, 
certain characteristics make enterococci excellent sentinels for monitoring changes in 
antimicrobial exposure.  As early as 1899 the enterococci were described as “very hard 
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and tenacious of life” (178).  In addition to their tolerance of heat stress, enterococci have 
also been shown to persist on dry surfaces for up to four months (314).  As members of 
the normal fecal microflora of many animals, enterococci can be found at high numbers 
in sewage treatment plants (23) and soil (106).  Isolates of common origin have been 
observed in humans, sewage, and poultry (23), poultry and humans (269,302,323), 
humans and cheese (26), and humans and meat foodstuffs (157).  The preponderance of 
data, however, suggests that distinct populations of enterococci are found in humans and 
food animals.   
Another important survival characteristic among enterococci is their promiscuous 
ability to readily acquire and transfer antimicrobial resistance elements (84).  Enterococci 
that are not able to colonize the human colon may be able to transfer resistance 
determinants to those strains that may be more host or tissue-adapted (269).  Porcine and 
avian strains can persist in the fecal flora of human volunteers between two weeks to 
several months (275).  Additionally, identical polymorphisms of the vancomycin 
resistance element vanA among E. faecium of food animal and clinical environments 
have been demonstrated (135,326) which illustrates the potential for the transfer of 
resistance determinants between the two populations.  Additionally, resistant E. faecium 
of food animal origin that have been observed to be transiently carried as part of the 
human intestinal microflora may potentially transfer resistance elements to host-adapted 
enterococci (275).   
Therefore, these observations suggest that Enterococcus spp. can be useful 
sentinel organisms to monitor the development of resistance resulting from the usage of 
antimicrobial agents in animal production. 
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Resistance to MLS Antimicrobials 
 The macrolide-lincosamide-streptogramin B antibiotics constitute the MLS 
superfamily because of their activity against the bacterial 50S ribosomal subunit to inhibit 
protein synthesis.  Streptogramin A components also exert an inhibitory influence on that 
area of the ribosome in a synergistic relationship with streptogramin B components.  
Cross-resistance between these important therapeutic drugs was first identified in 
staphylococci in 1956, only a few years after the introduction of erythromycin, and 
subsequently spread to France (47), the U.K. (109), and the U.S. (143).  Resistance to this 
group of antimicrobial agents subsequently spread to other genera including Bacillus, 
Actinobacillus, Lactobacillus, Clostridium, Klebsiella, Escherichia, Neisseria, 
Pediococcus, Staphylococcus, and Streptococcus species.  The MLS phenotype was first 
identified in Enterococcus in an isolate of E. faecalis in 1972 (61).  
 
MLS Resistance Genes 
Some of the resistance genes thus far identified in Enterococcus faecium that 
confer resistance to streptogramin combinations can also confer resistance to macrolide 
and lincosamide classes of antibacterial agents.  The mechanisms and mode of action of 
MLS resistance determinants are diagrammed in Figure 1.  Resistance genes identified in 
E. faecium that modify the target site include the rRNA methylases erm(A) and erm(B).  
Initially identified in staphylococci, these enzymes modify a specific adenine residue, 
A2058, which is located in the peptidyltransferase region of the bacterial 23S rRNA.  
This modification confers resistance to 14-member (erythromycin) and 16-member 
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macrolides (tylosin), lincosamides (lincomycin), and streptogramin B, also known as the 
MLSb resistance phenotype.  The erm(B) gene alone is thought to confer macrolide 
resistance above the proposed testing limits (229) although its quantitative effect on 
lincosamide resistance has not been detailed.  Resistance to a streptogramin B component 
does not confer resistance to a combined streptogramin and requires additional resistance 
elements to streptogramin A components.   
The hydrolase, vgb(A), has been described in enterococci and has activity against 
streptogramin B components (137).  The lincomycin and clindamycin transferase, 
encoded by lnu(B) in E. faecium, inactivates the antimicrobial by nucleotidylation (35).  
A major facilitator in E. faecium, which has not been thoroughly described and reduces 
the intracellular concentration of erythromycin, is encoded by the gene mef(A) (176).  
Similar to mef(A), but of questionable importance to antimicrobial resistance, is the 
putative ATP-binding transporter msr(C) (229)  
Rende-Fournier et al. (236) first identified vat(D) from a clinical isolate of E. 
faecium from urine as an element located on a 27 kb plasmid.  This gene encodes an 
acetyltransferase that transfers an acetyl group to streptogramin A, inactivating it.  
Subsequently, another acetyltransferase, vat(E), was described among E. faecium isolates 
(120). In a study of E. faecium isolated from broiler chickens and pigs, vat(D) was found 
to be localized to a large plasmid that could be conjugatively transferred, however no 
other genes known to confer resistance were found to be present among these isolates 
(117).  Description of the vat(E) gene indicated that it is not co-localized with vgb even 
though both resistance elements were found in the same isolate (120).  In Germany, the 
vat(E) gene predominates in isolates of poultry origin resistant to streptogramins (315) as 
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well as in isolates from human clinical samples (273).  Both vat(D) and vat(E) can be 
transferred conjugatively, but not all isolates that possess these genes are able to transfer 
the determinants in vitro, suggesting that a missing component is needed for conjugation 
(315).  Bozdogan et al. (36) have shown that with the combination of erm(B) and vat(D), 
the MIC of quinupristin-dalfopristin was 8 µg/ml.  Previous work involving the genes 
erm(B), vat(D), and vgb(A) suggests that the erm(B) rRNA methylase gene does not 
affect the combined streptogramin resistance levels in the absence of the acetyltransferase 
vat(D) (35).  This conclusion is borne out by the observations of resistance to 
quinupristin-dalfopristin and virginiamycin being much higher in isolates that possess 
either vat(D) or vat(E) (MIC >64 µg/ml) than those that do not (MICs 4 to 16 µg/ml) 
(273).  It is worthwhile to mention that some isolates that do not possess an 
acetyltransferase and yet are resistant to combined streptogramins represent as yet 
undescribed components that contribute to the MLS resistance phenotype. 
Soltani et al. demonstrated that the erm(B) gene was detected in 100% of 
European isolates that possessed vat(D) and in 79% of isolates that possessed vat(E), but 
the location of these resistance elements were not reported (273).  The combination of 
erm(B), vgb(A), and vat(D) has been observed among individual clinical isolates of E. 
faecium (35). 
 
Prevalence of MLS Resistance Genes 
Estimates of erm(A) prevalence among macrolide-resistant isolates from Spain 
reveal that it is infrequent (229).  There was an observed erm(A) prevalence in 1% of 
poultry and porcine isolates from Denmark, Finland, and Norway (6) and 5% of EU 
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clinical isolates (258).  The prevalence is apparently not different among streptogramin-
resistant isolates from Danish poultry (138).  Erm(B) is estimated to represent up to 88% 
of macrolide-resistant isolates of poultry and porcine origin in the EU (5,6).  The high 
prevalence of erm(B) was similarly observed among clinical isolates resistant to 
macrolides from European countries (229,258).  Analogous to the situation with erm(A), 
the prevalence of erm(B) is similar among streptogramin-resistant isolates from Danish 
poultry and pigs (138), and as well as those of clinical origin (35,273).  Less resistance 
was observed in a U.S. study of retail poultry products in which erm(B) was observed in 
41% of streptogramin-resistant isolates (267).   
The prevalence of the efflux pump mef(A) has been estimated to be as high as 
22% of U.S. clinical isolates of Enterococcus spp. (176), which is in contrast to the 
observed non-detection among enterococci from Belgian pork production environments 
(183).  A mef-like gene has been observed in a single clinical isolate from Spain (229).  
The msr(C) gene was initially described among clinical isolates of E. faecium as a likely 
intrinsic feature of the species (229).  Subsequent studies on the msr(C) confirmed the 
previous observation of conservation among E. faecium of clinical origin (270).  The 
gene contributed to a rise in erythromycin MIC by six-fold, but was not solely 
responsible for macrolide resistance.  Although the gene has been ascribed activity 
against lincosamide antimicrobials, the MIC was not markedly affected (270).  The 
incorporation of E. faecium from multiple sources in Germany revealed that the msr(C) 
gene could not be detected in 42% of isolates (315) with a subsequent study indicating its 
absence in 31% of isolates from poultry (316).  The nucleotidyltransferase lnu(B) 
[previously known as lin(B)] was described in a clinical isolate of E. faecium from 
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France.  This genetic element was demonstrated to be on a 240-kb plasmid and 
parenthetically described as present among all 14 isolates of E. faecium of clinical origin 
that inactivated lincosamides (34).  Upon curing of the plasmid, this isolate also lost its 
resistance to erythromycin, suggesting that the element that conferred macrolide 
resistance is either co-localized with lnu(B) or is located on another resident plasmid.  
Since the publication of this observation, lnu(B) has been described in only a single, 
lincosamide-resistant isolate of group B Streptococcus of clinical origin from Canada 
(66).  The initial description of the streptogramin B hydrolase vgb(A) among enterococci 
was in a clinical isolate of streptogramin-resistant E. faecium from The Netherlands 
(137).  Since its description, it has been identified in only one other instance, a clinical 
isolate from France (36).   
Known resistance elements that confer streptogramin A resistance to E. faecium 
include the acetyltransferases encoded by the genes vat(D) and vat(E).  The prevalence of 
vat(D) among isolates of poultry origin from Europe is estimated between 10 to 13% 
(6,138).  The gene was not detected in a recent survey of resistant isolates from U.S. 
retail poultry (267).  Among resistant isolates from pigs in European production 
operations, vat(D) has been found among 2 to 7% of isolates (5,6,138).  Comparative 
studies suggest that in addition to its more frequent isolation from pigs, vat(D) also is 
found more frequently among isolates of human origin (137,273,317).  A survey of 
clinical isolates from Spain, however, suggests that the predominant resistance 
mechanism may vary by region (241).  Vat(E) has been observed to be more frequently 
encountered among isolates of poultry origin and accounts for 72 to 100% of 
streptogramin-resistant poultry isolates from Europe (6,120,138,317).  In contrast, vat(E) 
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is estimated to be present among only 4 to 7% of resistant-isolates from pigs (5,138).  
Among resistant isolates from U.S. retail poultry, vat(E) was observed in 37% of resistant 
isolates (267).   
The erm(B) and vat(E) genes have been proven to be closely linked in a collection 
of E. faecium isolates from Germany (136).  This linkage is reported in 74% of all 
streptogramin resistant E. faecium from this region, notably from poultry sources.  Given 
that reports have long suggested transfer of resistance elements is both geographically 
and phylogenetically widespread (198,244) and that the erm(B) element has been found 
to have been duplicated in the clostridial genome (95), it is not unexpected that any of the 
targeted genes will be found in a similar arrangement in E. faecium. 
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Scope of Dissertation 
 The hypothesis examined in this dissertation is that the use of antimicrobial agents 
in the agricultural environment selects for resistant isolates of bacteria, especially the 
enterococci.  The increased prevalence of these resistant organisms in animal production 
or processing facilities may have the potential to compromise the therapeutic efficacy of 
related antimicrobials used in human treatment.  Enterococcal resistance to the clinically 
important macrolide, lincosamide, and streptogramin classes of antimicrobials is of acute 
interest due to the decline in antimicrobial treatment options.  Elements conferring 
resistance to these antimicrobials from U.S. poultry production isolates of Enterococcus 
faecium may not mirror human-derived isolates, but may have variable potential for the 
dissemination and subsequent establishment of resistance.  This hypothesis will be tested 
by pursuing three specific aims: 
 
I. Establish the populations of Enterococcus spp. from the poultry production 
environments of the Delmarva Peninsula. 
 
II. Establish a baseline of resistance among the isolated Enterococcus spp. to a 
number of antimicrobial agents used in animal production as well as the 
treatment of human disease. 
 
III. Characterize molecular determinants that confer the Macrolide-Lincosamide-
Streptogramin (MLS) resistance phenotypes among Enterococcus faecium 
from the poultry production environment. 
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Table 1.  Current and proposed Enterococcus spp. 
E. asini E. hirae 
E. avium E. malodoratus 
E. canis E. moraviensis 
E. casseliflavus E. mundtii 
E. cecorum E. pallens 
E. columbae E. phoeniculicola 
E. dispar E. porcinus 
E. durans E. pseudoavium 
E. faecalis E. raffinosus 
E. faecium E. ratti 
E. flavescens E. saccharolyticus 
E. gallinarum E. seriolicida a 
E. gilvus E. solitarius a 
E. haemoperoxidus E. sulfureus 
 E. villorum 
 
a Species have been shown to belong to other genera 
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Mechanism of action of resistance proteins is indicated in italics; arrows denote the target 






Isolation, Identification, and Antimicrobial Susceptibility Profiling of Enterococcus 




 The potential impact on the bacterial population of food animals in the production 
environment as a result of antimicrobial drug use for growth enhancement continues to be 
a cause for concern.  Enterococci from 82 farms within a poultry production region on the 
eastern seaboard were isolated to establish a baseline of susceptibility profiles to a 
number of antimicrobials used in production as well as clinical environments.  Of the 541 
isolates recovered, E. faecalis (53%) and E. faecium (31%) were the predominant species 
isolated, whereas multiresistant antimicrobial phenotypes were observed among all 
species with a proportionately greater diversity of resistance phenotypes observed among 
isolates of E. faecium.  Isolates of E. faecalis were more resistant to lincosamide, 
macrolide, and tetracycline antimicrobials whereas isolates of E. faecium were more 
resistant to fluoroquinolones and penicillins.  Notably, 63% of the E. faecium isolates 
were resistant to the streptogramin quinupristin-dalfopristin, whereas high-level 
gentamicin resistance was observed only among the E. faecalis population, of which 7% 
of the isolates were resistant.  The primary observations are that enterococci can be 
frequently isolated from the poultry production environment and can be multi-resistant to 
antimicrobials used in human medicine.  The high frequency with which resistant 
enterococci are isolated from this environment suggests that these organisms might be 
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useful as sentinels to monitor the development of resistance resulting from the usage of 
antimicrobial agents in animal production. 
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INTRODUCTION 
 Our anthropocentric view of human pathogens has historically caused us 
to think of bacterial resistance to antimicrobials as a problem arising purely out of 
clinically related events.  In fact, it is being increasingly recognized that antimicrobial 
resistance develops at a high frequency in food animal production.  The conundrum is 
whether the prevalence in this environment contributes to the problem being observed in 
the clinical sphere.  Enterococci can persist for long periods of time on surfaces in the 
clinical environment and can readily be transferred among the patient population, many 
of whom may be prone to colonization (218) with significant morbidity and mortality 
among predisposed patients (205).  Enterococcus spp., particularly E. faecalis and E. 
faecium, have presented serious challenges to the control of antimicrobial resistance as 
they are the second leading cause of nosocomial infections in intensive care units in the 
United States (44) and are becoming increasingly resistant to treatment with 
antimicrobials.  Additionally, infections caused by other Enterococcus species (E. durans, 
E. avium, E. raffinosus, E. gallinarum, and E. casseliflavus) occasionally occur and 
warrant attention (205).  Over twenty-four percent of nosocomial infections are 
complicated by the intrinsic resistance of this organism to many antibiotics as well as 
acquired resistance to vancomycin (132). 
The unprecedented cooperation of various clinical institutions has led to the 
development and maintenance of highly developed surveillance programs such as the 
National Nosocomial Infections Surveillance (NNIS) system of the Centers for Disease 
Control, while program monitoring of other environments is still in development, e.g., the 
National Antimicrobial Resistance Monitoring System (NARMS).  In spite of the efforts 
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in the clinical arena to monitor the incidence of antimicrobial resistance, the frequency of 
resistance continues to climb.  Description of the antimicrobial susceptibility profiles of 
pathogens isolated from non-clinical environments is comparatively limited because of 
the focused interest of investigators only on resistance to particular antimicrobial agents.  
The ability to evaluate the threat posed by antimicrobial resistance to the treatment of 
human disease is also complicated by differences seen geographically.  For example, in 
the case of Enterococcus spp., the high prevalence of vancomycin-resistant enterococci 
(VRE) observed in non-hospitalized human (community) populations of EU members has 
not been mirrored in the United States.  In contrast, the U.S. has a comparatively higher 
prevalence of VRE in the hospital environment (206,310).   
Past surveillance has also demonstrated a high prevalence of VRE in the food 
animal production environments of the EU as opposed to the U.S. where no VRE have 
been reported from studies of U.S. farms (185,310).  These observations strongly 
implicate the agricultural use of the glycopeptide avoparcin in EU operations in the 
development of resistance.  Explanations for the higher rate of occurrence of VRE among 
hospitalized U.S. patients have been ascribed to extensive use of vancomycin in the 
hospital environment. 
Increased concern over the selection for resistance through the use of analogues of 
human antimicrobials for growth promotion has led the EU to ban the use of all 
antimicrobials as feed additives.  Although existing evidence has not yet suggested that 
enterococci of environmental or foodborne origin should be regarded as bacterial 
pathogens, they could serve as potential reservoirs of virulence and antimicrobial 
resistance genes to host-adapted strains (103).  The 1999 FDA approval of quinupristin-
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dalfopristin (Q-D or Synercid®) for treatment of vancomycin-resistant E. faecium 
infections in humans has been met with similar concern due to the use of the analogue 
virginiamycin in U.S. agriculture for over 25 years.  The demonstration of resistance in 
the food production environment (118,124,313), food products (273), and the community 
(2) has raised concerns about the temporal efficacy of this drug in the clinical 
environment. 
Whereas the extent to which the selection and distribution of resistant human 
pathogens is related to the use of antimicrobials in agricultural is still hotly debated, few 
studies have actually detailed the multiresistant nature of enterococci from the food 
animal production environment to drugs used in production.  The purpose of this study 
was to characterize the species and related broad antimicrobial susceptibility profiles of a 
large number of Enterococcus spp. isolated from poultry production operations located 
on the eastern seaboard of the U.S. 
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MATERIALS AND METHODS 
Sample collection.  Samples were either poultry litter or swabs of poultry 
transport containers.  Surface poultry litter was collected from 55 roaster and broiler 
chicken houses located on the eastern seaboard of the U.S., as described previously (16).   
Over a period of eleven weeks in the summer of 1998, two swabs from each of 103 
poultry transport containers representing 27 farms were periodically collected at a 
regional processing facility.  Fecal material from six surface sites of each of the poultry 
transport containers at the facility was swabbed with sterile gauze using a five-inch 
diameter metal template, as described previously (235).  Swabs were immersed in 50 ml 
of Cary Blair medium in sterile specimen cups and litter samples were stored in sealed 
Whirl-Pak® bags (Nasco, Fort Atkinson, WI) and transported to the laboratory.  Two sets 
of pooled swabs were processed independently as shown in Figure 2.  The locations of 
the sampled commercial poultry production houses for which geographic data was 
available on the Delmarva Peninsula are diagrammed in Figure 3.  Data on the identity 
and quantity of antimicrobial use among the production environments were not available. 
 
Isolation and identification of Enterococcus spp.  Surface poultry litter was 
added at a 1:4 dilution to 40 ml of nalidixic acid-brain heart infusion-salt (NABS) 
enrichment broth for incubation at 35oC with agitation in a Series 25 rotary shaker 
incubator (New Brunswick Scientific, Edison, NJ).  Similarly, swabs of the poultry 
containers were removed from the Cary-Blair media, pooled in sets of three and placed in 
40 ml of NABS broth and incubated as described above.  Enterococci were cultured by 
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transferring 100 µl of broth to using colistin-nalidixic acid (CNA) and bile esculin azide 
(BEA) agars (Difco).   
Isolates were presumptively characterized as enterococci based on Gram stain, 
catalase reaction, tolerance to 6.5% NaCl and growth at 45oC, the production of 
pyrolidonylarylamidase (PYR), and hydrolysis of esculin in the presence of bile.  
Confirmation to the genus level was accomplished using the Enterococcus AccuProbe® 
Culture Identification kit (Gen-Probe, Inc., San Diego, CA) according to the 
manufacturer’s specifications.   
Identification to species or group was performed using a miniaturized 
identification system based on the biochemical tests recommended by Facklam and 
Collins (93), which included the utilization of R-mannitol, R-sorbitol, L-sorbose, R-
raffinose, and L-(+)-arabinose (Sigma-Aldrich, St. Louis, MO) performed in Costar® 96 
well cell culture plates (Corning, Inc., Corning, NY), as well as assays for the presence of 
methyl-α-D-glucopyranosidase and arginine dihydrolase.  Twenty microliters of a 
visually prepared McFarland 1 suspension of fresh bacterial growth was added to 200 µl 
of each test well of a 96-well microtiter plate.  The plate was covered and incubated at 35 
oC for 18±1 h.  Supplementary testing included ribose, sucrose, and inulin utilization as 
well as assays for motility when additional discrimination was required between two or 
more species.  These results were then compared to those of conventional tube tests run 
in parallel.  Control strains used in identification included ATCC strains E. faecalis 
51299, E. avium 35665, E. pseudoavium 49372, E. raffinosus 49427, E. malodoratus 
43197, E. faecium 35667, E. mundtii 43186, E. casseliflavus 25788, E. gallinarum 49573, 
E. durans 49479, E. hirae 10541, E. dispar 51266, E. sulfureus 49903, E. saccharolyticus 
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43076, E. columbae 51263, and E. cecorum 43198.  The VITEK (bioMérieux) microbial 
identification system was used to supplement identification.  Isolates and control strains 
were frozen at -80oC in Trypticase Soy broth supplemented with 20% glycerol.   
 
Susceptibility testing.  The minimum inhibitory concentrations (MIC) for 28 
antimicrobials were determined for each of the isolates using the SensititreTM 
antimicrobial susceptibility testing system (Trek Diagnostic Systems, Inc., Westlake, 
OH) as seen in Figure 4.  Particular antimicrobials and/or analogs used in human and 
food animal production environments are listed in Table 2 with test concentrations and 
interpretative criteria for resistance breakpoints for each drug as available (213).  
Additionally, isolates were tested for resistance to vancomycin and for high-level 
resistance to gentamicin, kanamycin, and streptomycin.  Approximately 5 X 105 CFU/ml 
of each isolate, suspended in Mueller-Hinton broth, were inoculated into microtiter plates 
containing the test antimicrobials and incubated at 37oC for 18 ± 1 h. in ambient air.  E. 
faecalis strains ATCC 29212 and ATCC 51299 were used as quality controls.  The plates 
were removed and read manually for growth to score the MIC determinations using 
available NCCLS interpretive criteria (213).  Ambiguous or inconclusive observations 
were repeated. 
 
Antibiogram exclusion analysis.  Antibiograms of the isolates from all samples 
were compared in relation to the farm and species designation.  Enterococcal 
antibiograms from different isolates from the same farm that differed by less than two 
 32
dilutions for one or more antimicrobial MICs were considered duplicate isolates and only 




Performance of the microtiter identification method.  To evaluate the 
consistency of the microtiter adaptation to traditional biochemical assays, five repetitions 
of the ten biochemical tests were conducted using the ATCC control strains of 
Enterococcus spp. listed in Table 3.  The results of the microtiter adaptation essentially 
were identical to those of the traditional tube-based biochemical tests.  No variability was 
observed within the species with the exception of the raffinose reactions of E. faecium 
and E. dispar, in which aberrant reactions were observed in 1/5 tests of the biochemical 
panel.  Observations were most discriminatory when the plates were observed at 18 h 
compared with observations at 16 and 24 h.   
 
Isolation and identification of enterococcal species.  Of the over 1000 isolates 
screened from over 100 litter and 70 crate swab samples, 541 were subsequently 
identified as enterococci.  A large proportion of those isolates that were initially isolated 
and later discarded appeared to be gram-positive pleomorphic rods that were catalase 
positive.  Additionally, there were numerous occasions in which a rapidly swarming and 
mucoid microorganism overgrew the plate and precluded the isolation of other resident 
bacteria.   
All enterococcal isolates were identified to species and antimicrobial 
susceptibility profiles were established.  This collection was reduced to 331 unique 
isolates after the removal of isolates of the same species from the same farm with non-
distinct susceptibility patterns (Table 4).  There were no apparent differences in the 
species prevalence or their associated susceptibility profiles of enterococci isolated from 
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litter and from poultry transport containers.  E. faecalis was the predominant species 
(53.2%) identified followed by E. faecium (31.4%), E. gallinarum (6.0%), E. hirae 
(3.9%), E. durans (1.5%), E. casseliflavus (1.2%), and E. avium (0.3%).  Eight isolates 
that were not clearly identifiable to species using biochemical means were placed into 
groups established by Facklam and Collins (93) based on the fermentation of mannitol 
and the activity of arginine dihydrolase. 
 
Multiresistance phenotypes of Enterococcus spp.  Reduced susceptibility to 
antimicrobials used in the poultry production environment was prevalent among the 
isolates (Table 5).  Reduced susceptibility to lincosamide antimicrobials was most often 
encountered, occurring in 98.5% across all species, followed by streptogramin (78.3%), 
tetracycline (68.0%), macrolide (54.3%), and penicillin (26.7%).  No isolate was resistant 
to all five classes examined, but 52.7% were co-resistant to four antimicrobials.  
Multiresistance profiles to the selected antimicrobials were quite diverse with the 
lincosamide-macrolide-streptogramin-tetracycline (36%), lincosamide-streptogramin-
tetracycline (19%), and lincosamide-penicillin-streptogramin-tetracycline (11%) 
phenotypes, most commonly observed on a percentage basis owing largely to the 
purported intrinsic resistance of the large number of E. faecalis isolates to streptogramin 
antimicrobials in the data set.  The lincosamide-penicillin -streptogramin-tetracycline 
(23%), lincosamide-streptogramin-tetracycline (14%), and lincosamide-macrolide-
penicillin -streptogramin-tetracycline (11%) resistance phenotypes were otherwise the 
most common multiresistance patterns observed among all isolates.  Isolates of E. 
faecium demonstrated the largest diversity of multiresistance phenotypes (18) followed 
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by E. hirae (8) and E. gallinarum (6) compared to the five observed among the larger 
population of E. faecalis isolates.  There were no observed isolates of vancomycin-
resistant E. faecium or E. faecalis. 
 Resistance to high-level aminoglycosides was prevalent across all species except 
for a single isolate of E. avium (Table 6).  The observed frequency was highest among 
isolates of E. faecium (68%), followed by Group III Enterococcus spp. (67%), E. faecalis 
(53.7%), E. casseliflavus (50%), E. durans and E. gallinarum (40%), E. hirae (30%), and 
Group II Enterococcus spp (20%).  The patterns of resistance to high-level 
aminoglycosides revealed that resistance to streptomycin was most prevalent across all of 
the isolates except for E. hirae, followed by kanamycin and co-resistance to streptomycin 
and kanamycin.  Resistance to high-levels of gentamicin was only observed among 
isolates of E. faecalis and only occurred in conjunction with high-level kanamycin 
resistance. 
 
 Susceptibility profiles of E. faecalis and E. faecium isolates.  The susceptibility 
profiles to antimicrobial agents used in the food animal production environment and their 
human analogues were examined using the two largest populations recovered from 
sampling: E. faecalis and E. faecium.  There was no overlap of MICs for bambermycin 
(flavomycin), between E. faecalis and E. faecium, which had modes of 2 and >32 µg/ml, 
respectively (Figure 5). 
 Among the cephalosporin antimicrobials cefazolin and cephalothin, there were no 
observed differences between E. faecalis and E. faecium with 94 – 100% resistance 
among both populations (Figures 6 and 7).  Similarly, no differences in susceptibility 
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profiles were observed between the two populations to chloramphenicol with both 
populations susceptible to chloramphenicol although more variance was observed among 
E. faecium isolates (Figure 8). 
Fifty-two percent of E. faecium isolates were resistant to ciprofloxacin at 
≥4 µg/ml, whereas only 1.7% of the E. faecalis isolates were resistant (Figure 9).  As 
seen in Figures 10-12, the greater resistance of E. faecium compared to E. faecalis was 
consistent among the other tested fluoroquinolones (lomefloxacin, norfloxacin, and 
ofloxacin).  The susceptibility profiles of both populations were remarkably consistent to 
lomefloxacin and ofloxacin.  Norfloxacin, in contrast, appeared to be the most active 
fluoroquinolone with only 2.9% of E. faecium resistant. 
Whereas E. faecalis had a broader distribution of vancomycin MIC values (≤0.5-4 
µg/ml) than E. faecium (≤0.5-1 µg/ml), no isolate of either species was resistant (Figure 
13).  In contrast, MIC values to the ionophore salinomycin were more evenly distributed 
among E. faecalis isolates than those of E. faecium (Figure 14).  In addition, over 48% of 
E. faecium isolates were one dilution away from the resistance breakpoint. 
Among the lincosamide class of antimicrobials, E. faecalis isolates were resistant 
to clindamycin (Figure 15) and by analogy to lincomycin which does not have 
interpretive criteria (Figure 16) whereas the profile of the population of E. faecium 
appeared highly resistant (84%) to the tested lincosamide antimicrobials.  Greater 
dispersion of MIC values was observed among isolates of E. faecium. 
Among the tested macrolide antimicrobials, resistance was higher among E. 
faecalis isolates (67-69%) compared to E. faecium isolates (13.5-34%).  The distributions 
of MIC values among both populations to clarithromycin (Figure 17) and erythromycin 
 37
(Figure 18) were comparatively more uniformly distributed than the distribution observed 
to tylosin (Figure 19).  Two modes were observed among all macrolide distributions of E. 
faecalis isolates whereas three modes were observed among E. faecium susceptibility 
profiles to erythromycin and two modes for clarithromycin and tylosin. 
Only a single isolate of E. faecium was observed to be resistant to ampicillin, 
although 50% of the entire population of E. faecium had an ampicillin MIC of 8 µg/ml, 
one dilution less than the NCCLS breakpoint (Figure 20).  Both species were observed to 
be almost uniformly resistant to oxacillin (Figure 21).  Differences were apparent among 
susceptibility profiles of penicillin with 71% of E. faecium isolates resistant to penicillin 
compared with none of the isolates of E. faecalis (Figure 22).  Interestingly, the 
distribution of penicillin MIC values among E. faecalis was tightly clustered (1-4 µg/ml) 
whereas E. faecium MICs were broadly distributed (≤0.03->32 µg/ml). 
Over 93% of E. faecalis and 100% of E. faecium isolates were observed to be 
resistant to the peptide bacitracin (Figure 23).  Interestingly, 90% of E. faecalis and 92% 
of E. faecium isolates had MICs in excess of the upper limit of the tested range (>256 
IU/ml).  A larger proportion of E. faecalis isolates (10.2%) were observed to be more 
resistant than E. faecium isolates (2.9%) to rifampin (Figure 24).  Additionally, the 
population of E. faecalis isolates had more evenly distributed MIC values across the 
tested range than E. faecium.   
Only seven isolates of E. faecalis were observed to have a MIC to quinupristin-
dalfopristin less than 4 µg/ml, whereas the resistance rate among E. faecium was 63% 
(Figure 25).  The distributions of virginiamycin MIC values of both populations were 
more dispersed than those of quinupristin-dalfopristin (Figure 26).  In particular, two 
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modes were observed among MIC distributions of E. faecium to the streptogramin 
antimicrobials: 2 and 16 µg/ml (quinupristin-dalfopristin) and 1 and 16 to 32 µg/ml 
(virginiamycin). 
Both species were observed to have high resistance rates to tetracycline (79-91%) 
as well as a distinct separation of resistant and sensitive populations (Figure 27).  The 
susceptibility profiles of both species to ampicillin/sulbactam were unremarkable in that 
no resistance and very little variance were observed (Figure 28).  Whereas both species 
presented a similar susceptibility profile to trimethoprim/sulamethoxazole, only a single 
isolate of E. faecalis was found to be resistant (Figure 29). 
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DISCUSSION 
The identification of enterococci isolated from the commercial poultry production 
environment did not reveal any unusual species, although eight isolates require more 
discriminant analyses prior to definitive identification.  Whereas multiple isolates were 
occasionally recovered from the same sample, the elimination of isolates with 
indistinguishable antibiograms from the same farm provided a collection that was 
conservative in its estimation of diversity, but did not substantively affect the relative 
proportions of species isolated.   
The finding of E. faecalis predominance in this study was similar to that 
previously reported for poultry production environments in other parts of the U.S. 
(196,313) as well as Belgium (40), the United Kingdom (20,148-150), and Denmark (2). 
Studies from Japan (329), in contrast, suggested that E. faecium was the dominant 
enterococcal species of poultry fecal flora whereas a Belgian study demonstrated a 
predominance of E. cecorum in older chickens (69).   
The degree to which enterococcal populations from the food animal production 
environment enter the human microbiota is likely heavily influenced by the degree of 
contamination of the foods consumed.  Recent surveys of U.S. retail meat products have 
demonstrated enterococci can be observed among 82-100% of samples (123,186).  
Contrary to the observations described in this study, E. faecium has been demonstrated as 
the largest enterococcal population among retail poultry and beef but not pork (123).  
E. faecalis accounts for 80-90% of enterococcal isolates of clinical origin, with E. 
faecium the second most prevalent enterococcal species.  Other species, such as E. avium, 
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E. durans, E. gallinarum, E. casseliflavus, E. hirae, E. mundtii, and E. raffinosus have 
been documented as causing disease, although infrequently, in humans (205).   
Because of the apparent ubiquitous nature of enterococci in the environment, only 
a sufficiently large epidemiological study of multiple ecological niches would be robust 
enough to demonstrate the population dynamics within the ecosystem.  It is important to 
note that the observed variances in species from the commercial poultry production 
environment observed in this study may be difficult to directly compare to other works 
due to the established effects of differences in isolation methodology (39) and the effect 
of medicated feed on the intestinal enterococcal microflora (18,20,149,196).  Preliminary 
studies conducted in at the FDA (Center for Veterinary Medicine, Laurel, MD) suggest 
that the incubation temperature used during selective enrichment of samples may affect 
the recovery of various enterococcal species. 
The rapid rise in antimicrobial resistance observed among human bacterial 
pathogens has brought into question the use of certain similar antimicrobials in both the 
human clinical and the food animal production environments.  Analyses for antimicrobial 
resistance among targeted bacterial populations from these defined environments have 
often overlooked the more complex presentation of resistance to multiple antimicrobials.  
The isolated Enterococcus populations from the commercial poultry production 
environment of the eastern seaboard of the U.S. in this study were also examined for the 
occurrence of co-resistance among antimicrobials employed in agriculture and in human 
medicine.   
 Phenotypic grouping based on the susceptibility to multiple antimicrobials that are 
frequently used in the poultry production environment provided some important 
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observations.  Most apparent is the magnitude of resistance to individual classes of 
antimicrobials across all isolated Enterococcus spp. with 98.5% resistant to the 
lincosamide, lincomycin; 78% resistant to the streptogramin, quinupristin-dalfopristin; 
68% to tetracycline; 54% to the macrolide, erythromycin; and 27% to penicillin.  
Whereas the indeterminate nature of Group II and III isolates and the limited data sizes of 
E. avium, E. casseliflavus, and E. durans preclude generalizations, the diversity of 
observed antibiograms, especially among isolates of E. faecium and E. hirae, is striking 
given the larger population of E. faecalis.  Interestingly, 63% of E. faecalis isolates 
demonstrated multiresistance to lincosamide, macrolide, streptogramin, and tetracycline 
classes of antimicrobials whereas the largest subset of E. faecium isolates demonstrated 
multiresistance to lincosamide, penicillin, streptogramin, and tetracycline antimicrobials.  
Acquired resistance elements that confer cross-resistance to macrolide-lincosamide-
streptogramin antimicrobials have been well described among enterococci (240) and have 
been associated with co-resistance to tetracycline, chloramphenicol, and high-level 
gentamicin (331), tetracycline and chloramphenicol (224), or chloramphenicol (315).  
Isolates that express these resistance elements may be phenotypically characterized as 
resistant to macrolide and lincosamide classes with streptogramin resistance dependent 
upon the presence of other resistance elements (35).  However, there were individual 
instances of isolated lincosamide and macrolide resistant phenotypes, as well as isolates 
that possessed co-resistance to lincosamide and streptogramin antimicrobials in the 
absence of macrolide resistance.   
There are few published quantitative descriptions of multiply resistant phenotypes 
observed among Enterococcus spp. in the U.S., especially those from the poultry 
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production environment.  Data from a Danish study illustrate the diversity of resistant 
phenotypes encountered among E. faecalis and E. faecium isolated from poultry as well 
as the frequent association of the resistance of macrolides and tetracycline with other 
antimicrobials (2).  Streptogramin-resistant E. faecium from this study also appeared 
more likely to be resistant to tetracycline than the population of streptogramin-sensitive 
isolates, which is consistent with anecdotal descriptions of isolates from U.S. retail 
chicken, but were not more likely to be resistant to penicillin (186).  Our results also 
suggest that streptogramin-sensitive isolates were more likely to be resistant to 
macrolides. 
Consistent with poultry studies from Japan (329) and Denmark (2), high-level 
gentamicin resistance was only observed in this study among E. faecalis isolates, 
although a Belgian report has demonstrated higher rates among E. faecium (40).  High-
level aminoglycoside resistance is a comparatively more frequent occurrence among 
enterococci of clinical origin as compared with those from the general community in the 
U.S. (75).  The observation of increased frequency of high-level gentamicin resistance 
among E. faecalis from this study has also been demonstrated among enterococci of 
clinical origin in the U.S. (75,308).  Additionally, high-level gentamicin resistance was 
only found in isolates that were also resistant to high-level kanamycin which is consistent 
with studies of clinical enterococci (308,331).  Similar to the observations of enterococci 
of poultry origin from Denmark, resistance to multiple aminoglycosides at high-levels 
was observed among the largest populations of this study with isolated high-level 
streptomycin resistance a predominant phenotype (2).  A higher prevalence of high-level 
streptomycin resistance was also seen among E. faecalis and E. faecium isolates of 
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animal origin from the U.S. (288).  Molecular studies of multiple high-level 
aminoglycoside resistance among Enterococcus spp. suggest that phenotypic antibiogram 
profiles belie the tremendous diversity of mechanisms that contribute to multiresistance 
(163).  Indeed, enterococcal isolates resistant to multiple aminoglycosides at high levels 
account for the overwhelming majority of isolates of clinical origin that are also resistant 
to vancomycin (75).   
Resistance to the production drug flavomycin, a bambermycin antimicrobial, has 
been previously described as an intrinsic characteristic among E. faecium from food or 
food production environments (40,79), whereas increased tolerance (MIC > 2 µg/ml) 
among E. faecalis isolates is rare (40,79).  Whereas these observations are similar to 
results presented here, resistance among E. faecium from Norway, which has not used 
flavomycin, do not follow this accepted pattern, suggesting that resistance to flavomycin 
may be an acquired trait (6).  Comparatively decreased susceptibility among E. faecium 
compared to E. faecalis to the bambermycin flavomycin has been previously ascribed to 
intrinsic resistance differences between the two species (40,78,79) although reduced 
tolerance among E. faecium from unexposed environments suggests otherwise (6). 
Cephalosporins are rarely used to treat enterococcal infections, ostensibly due to 
their reported intrinsic resistance.  Between 32 and 73% of environmental enterococcal 
isolates have been described as resistant to cefazolin and cephalothin (161,223).  Similar 
to our results with isolates from the poultry production environment, a 1994 U.S. survey 
revealed that 91% of bloodstream infection isolates and 87% of urinary tract infection 
isolates were resistant to cefazolin (141).  As a result, the use of cephalosporins has been 
shown to lead to superinfection or increased prevalence of Enterococcus spp. among the 
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fecal microflora (144).  In contrast to the consensus opinion, however, the incidence of 
resistance among isolates from chicken, beef, and milk from Africa was observed to be 
present among 17 to 34% of enterococci (50).  One explanation for this discrepancy may 
be the positive effect that exogenous sodium chloride in the suspension medium has upon 
MIC values of E. faecalis, thereby reducing the observed susceptibility of the isolates 
(179).   
Although chloramphenicol is not commonly used in the food production 
environment, resistance is observed at levels of 5 to 10% of E. faecalis and 0 to 4% of E. 
faecium isolates from poultry in the U.S. (196).  Prevalence of resistance in poultry 
production environments has been similarly observed at higher rates among E. faecalis 
than E. faecium in Japan (329) and Denmark (2).  Chloramphenicol resistance of 
enterococci isolated from the healthy community of the U.S. has essentially not been 
observed (75).  An increase in resistance has, however, been observed among clinical 
enterococci from the U.S. with 1% from 1953 to 1954 (15) to 7 to 14% today (194).  
Resistance rates to chloramphenicol among enterococci are also higher in clinical 
environments in the EU with resistance more frequent among isolates of E. faecalis than 
E. faecium (261).  Although chloramphenicol resistance has been associated with 
multiple drug resistance among clinical isolates from the U.S. (331) and the EU (261), it 
has been shown to be a potentially effective therapy for treating resistant bacteremia 
(237).  This suggests that the window of opportunity for treating resistant enterococcal 
infections with chloramphenicol might rapidly close following a more widespread 
clinical use of and subsequent resistance development to the antimicrobial. 
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Resistance to the fluoroquinolone ciprofloxacin has not previously been 
recognized among enterococci from the U.S. poultry production environment, ostensibly 
due to a lack of interest in non-mobile resistance, as the resistance mechanism is due to 
mutations in DNA gyrase or topoisomerase IV.  These observations of ciprofloxacin 
resistance across all species (18%) is similar to that observed among enterococci of 
poultry origin from the Netherlands (28%) despite the striking differences in resistance 
among E. faecium (52%) and E. faecalis (2%) observed in this study (302).  Resistance to 
ciprofloxacin is common among clinical isolates of enterococci (142,259) and more 
frequently observed in E. faecium than E. faecalis (259).  Ciprofloxacin resistance in the 
clinical environment has also been shown to have increased from 1.4% in 1986 to 51% in 
2000 (208,254).  Multiple resistances to other antimicrobials have been observed, with a 
strong correlation to high-level aminoglycoside resistance (261), but no such association 
was observed in this study.  Treatment of enterococcal infections with ciprofloxacin has 
been shown to reduce the gut enterococcal population (90) and select for E. faecium in 
studies among healthy volunteers (90), but has not been strongly endorsed as a course of 
therapy (98).  Data on the resistance to lomefloxacin, norfloxacin, and ofloxacin is 
sparse, but the evidence suggests that resistance is similarly more frequently encountered 
in the clinical setting (75,161).  Clinical resistance has been estimated among 98%, 27%, 
and 45 to 68% of clinical isolates to lomefloxacin, norfloxacin, and ofloxacin, 
respectively (129,141,161).   
Vancomycin-resistant enterococci have not been isolated from food animal 
production environments in the U.S. (121,145,288,313), or processing environments (28), 
consistent with our observations.  Similarly, VRE have not been isolated from domestic 
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retail meats (59,123,134,161,288).  In contrast, the selection of resistant populations by 
the use of the glycopeptide avoparcin in food animal production environments in Europe 
(1,6,7,18,40,78,279,299) has resulted in the frequent isolation of VRE from retail meat 
products (22,156,157,160,169,233,303,311).  The persistence of VRE on farms that have 
discontinued the use of avoparcin for growth promotion illustrates the impact posed by 
prior antimicrobial usage in food animal production environments (17,30,31,126,164).  
Most of these studies demonstrate an initial drastic decline in the prevalence of 
vancomycin-resistance followed by a stabilization at a constant low, but detectable level.   
The observation of decreased susceptibility of E. faecium compared to E. faecalis 
isolates to the ionophore salinomycin seen in this study, especially those of poultry 
origin, is consistent with previous ionophore susceptibility results from production 
environments of Denmark (4), but differs from those of broiler origin from Japan (329) 
and Belgium (40).  Salinomycin is widely used in the food animal production 
environment and this use is likely to increase as industry continues to limit the use of 
antibiotics in agriculture.  The resulting increase in selective pressure may then result in 
the development of detectable resistance.  As this antimicrobial agent is not used in 
human medicine, it is unlikely that clinical surveillance systems would monitor changes 
in susceptibility.  A future observation of decreased susceptibility (>8 µg/ml) among 
clinical isolates would serve to support the contention that enterococci of poultry origin 
play a role in directly contributing to human disease.  If, however, the prevalence of a 
phenotype of decreased susceptibility to salinomycin increases sufficiently in the poultry 
environment and no similar increase is observed among clinical isolates, the 
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independence in terms of colonization and carriage of the two populations would be 
supported. 
Resistance to the lincosamide class of antimicrobials is common among 
enterococci and has been reported to be an intrinsic trait among enterococci (192).  This 
type of resistance has been described as specific for Enterococcus spp. as well (79).  
More recent evidence has shown that resistance diminishes following the removal of 
lincosamide antimicrobials from the pork production environment (29), suggesting that 
resistance is an acquired trait.  Among isolates from the poultry production environment, 
greater than 60% of E. faecium and 85% of E. faecalis have been observed to be resistant 
to clindamycin (329), whereas elevated lincomycin MICs were observed among 3 to 16% 
of enterococci from the UK production environment (148).  Resistance to lincosamide 
antimicrobials has been observed at high rates in both E. faecalis and E. faecium from 
community (75) and clinical sources (75,194), with more homogeneous resistance among 
E. faecalis (75), which were consistent with our observations. 
Congruent with the results of this study, others have reported that resistance to the 
macrolide antimicrobials erythromycin and tylosin is frequent among enterococci from 
the poultry production environments (2,7,148,302,329) and from those of clinical origin 
(2,75,186,194,261).  The rapid development of erythromycin resistance in the poultry 
production environment as the result of medicated feed use (6,196) as well as exposure to 
tylosin (51) and virginiamycin (7) has been documented.  The prevalence of macrolide 
resistance is higher among enterococci of clinical origin than among those isolates from 
the community (75) except those associated with the poultry production environment 
(302).  Resistance is also more often observed in E. faecium than E. faecalis (75,261).  
 48
Whereas only 3% of U.S. clinical isolates were found to be resistant in the period 
between 1953 and 1954 (15), the rise was appreciable among isolates from 1968 to 1969 
(290), and resistance continues to rise with rates presently approaching 100% (142).  
Little information is available regarding the susceptibility of enterococci to 
clarithromycin, but resistance appears to mirror that of erythromycin (170).  Intestinal 
microflora studies have demonstrated that clarithromycin can increase the prevalence of 
fecal enterococci from humans (82).  The association and possible horizontal transfer of 
macrolide resistance among enterococci, in conjunction with resistance to other 
antimicrobials, continues to be a source of concern (224,315). 
In contrast to a study in 1986 of enterococci from U.S. poultry production 
environments in which penicillin resistance was reported among 18 to 33% of E. faecium 
and 5 to 11% of E. faecalis isolates, 71% of E. faecium and 0% of E. faecalis isolates 
from this study were resistant (196).  Consistent with results from Japan (329), Denmark 
(2), and Belgium (40), between 14 and 78% of E. faecium from the U.S. poultry 
production environment were observed to be resistant to ampicillin whereas no resistance 
was observed among E. faecalis (313).  Worldwide, E. faecium are usually more resistant 
to penicillin than E. faecalis in isolates of clinical origin (252), a pattern also seen with 
ampicillin (33,75,142).  Resistance to oxacillin, in contrast, appears to be a trait common 
to all enterococci regardless of origin (161).  Resistance to penicillin and its congeners 
has been increasingly observed among E. faecium isolates in clinical environments (33).  
Among healthy individuals, ampicillin-resistant enterococci have not been observed in 
the U.S. (75), whereas in the UK only 1% of isolates were resistant (115). 
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The prevalence of increased resistance to the peptide bacitracin among the 
predominant enterococci from this study is greater than those from poultry and pig 
operations in Denmark (2).  It is notable that bacitracin resistance among E. faecium of 
poultry and porcine origin was much lower in Finland, where its use had been eliminated 
four years earlier (6).  Although in vitro studies have suggested that bacitracin may select 
for vancomycin resistance by induction (167), no such association has been found in 
Danish poultry and pig production (18).  Among clinical isolates in the U.S., an increase 
in resistance to bacitracin was observed between 1953 and 1968 (290).  
Resistance to rifampin has been estimated at 16% of enterococci from raw meat 
products (223).  Among environmental isolates, 28% of E. faecalis and 53% of E. 
faecium isolates were resistant to rifampin (161).  Similarly, 36% of E. faecalis and 57% 
of E. faecium isolates of clinical origin from Lebanon were resistant (335).  Rifampin 
resistance was observed at a higher prevalence among E. faecium from hospitalized 
patients (73%) than from those in the community (43%) whereas the prevalence was 
higher among E. faecalis from the community (35%) as compared with those of hospital 
origin (29%) (75).   
Resistance to quinupristin-dalfopristin (Q-D) among food animal production 
environments in the U.S. is not surprising, given the use of the analog virginiamycin on 
farms since 1974 (124,313).  E. faecalis isolates have been shown to be intrinsically 
resistant to streptogramins (271), however the recent observation of transferable 
resistance in this species may provide some insight into the resistance seen among other 
species (268).  The incidence of resistance to the streptogramin has increased to 100% in 
older turkey flocks that are fed the analog virginiamycin (313) whereas the prevalence of 
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Q-D-resistant E. faecium (QDREF) from the U.S. chicken production environment has 
been estimated to be between 51 and 78% (124).  The increased frequency of Q-D 
resistance among E. faecium from turkey compared to chicken might be related to the 
different periods of time that the flocks are exposed to antimicrobials prior to slaughter 
(124).  Resistance has been observed among 70 to 79% of E. faecium from Denmark 
poultry farms (2,6) compared with 0 to 17 % in countries in which virginiamycin is not 
used (6) and mirrors changes in use on the farm (7).  A study of isolates from chicken 
production environments of Japan has demonstrated resistance to the analog 
virginiamycin at 27% among E. faecium (329).  The bimodal distribution of MIC values 
observed in that study is consistent with our observations.   
The prevalence of resistance of isolates from marketed poultry meat has been 
estimated between 3 to 26% of E. faecium from raw chicken samples by U.S. 
surveillance studies (123,186).  Estimates of human carriage of QDREF range from 0 to 
1% in the U.S. (75,186) to 11% of those abroad (2).  Virginiamycin use in the poultry 
industry has been closely linked to the increased prevalence of QDREF among those 
members of the community associated with the poultry production environment (302).  
Among clinical isolates, rates range from 8 to 19% from the U.S. (75) and 8 to 38% in 
the EU (261).  It is notable that E. faecium that are resistant to vancomycin are more 
resistant to Q-D (56).  Resistance to vancomycin and Q-D has been reported among 
isolates from British chicken and hospitalized persons (327) and co-localization of the 
resistance elements has been observed in a clinical strain from France (36). 
Resistance to tetracycline among Enterococcus spp. is very common, especially 
among those of poultry origin in the U.S. (196,321) and abroad (40,329).  Tetracycline 
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resistance also has been demonstrated to be linked closely to the poultry production 
environment (302), which is similar to the observations in this study.  Among enterococci 
of clinical origin, the resistance rate has increased from 54% in 1954 (15) to 80% of those 
observed between 1964 and 1973 in the U.S. (194).  Similar to observations of this study, 
a bimodal distribution has been reported elsewhere (325). 
There is no previous measure of ampicillin/sulbactam (A/S) resistance outside of 
the clinical environment with which to compare our results.  Estimates of clinical 
resistance to A/S suggest that 17 to 87% of E. faecium are resistant (182,189,225) 
compared with less than 1% of E. faecalis (182,225).  The combination of A/S has seen 
increased interest as either a sole (171) or combination therapy (109,184) to treat 
enterococcal endocarditis and bacteremia (189).  There is concern, however, that the use 
of A/S may increase the density of VRE among the fecal microflora of colonized humans 
due to the anti-anaerobic activity of this therapeutic combination (73).  Given the 
disparate rates of A/S resistance among E. faecium from poultry and from clinical 
medicine, this suggests that little pressure is applied in the poultry production 
environment to select for this resistance trait.  An alternative explanation may be that 
clinical surveys of Enterococcus spp. reflect a distinct population that has been 
disseminated widely in that environment and introduced a bias in the prevalence of A/S 
resistance. 
 The single isolate of E. faecalis that was observed to be resistant to 
trimethoprim/sulfamethoxazole (T/S) represents the first description of such a phenotype 
from the poultry production environment.  By comparison, resistance has been estimated 
at 31% among isolates from raw meat in Italy (223).  The interest in treatment of 
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enterococcal infections with T/S stems from the successful use of the antimicrobial 
combination to treat resistant infections (292).  Enterococci are usually susceptible to low 
levels of T/S although E. faecium has been shown to be more resistant to T/S than E. 
faecalis among enterococci from the clinical environment (62).  Comparisons to past 
work in the literature are complicated by the observation that in vitro susceptibility may 
be dramatically affected by media components and may not reflect the true in vivo 
activity of the antimicrobial combination (332).  
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CONCLUSIONS 
The recent observations of enterococcal vancomycin resistance elements among 
U.S. clinical isolates of S. aureus suggest that alternative therapies, such as linezolid and 
Q-D, will be more frequently employed (45,46).  As a result, resistant populations of 
enterococci that may have entered the human microflora through the consumption of 
contaminated retail meat products may be amplified following the inevitable increase in 
selective pressure in the clinical environment. 
The results of this study illustrate that Enterococcus spp. are frequently resistant 
to multiple antimicrobials and that some of these patterns may arguably reflect the use of 
approved antimicrobials in poultry in the U.S.  Considering some of the current estimates 
of the extent of antimicrobial use in the poultry production industry for growth 
enhancement, the increasing potential of such an intensive agricultural operation to effect 
antimicrobial resistance must be weighed against the reasonable risk that treatment of 


























































































































































































































Table 2. Antimicrobial susceptibility testing for Enterococcus spp. isolates 





Aminoglycoside Gentamicin 64 – 2048 >500 
 Kanamycin 64 – 2048 >500 
 Streptomycin 128 – 2048 >1000 
Bambermycin Flavomycin 0.5 – 32 >8b 
Cephalosporin Cefazolin 2 – 16  >16 
 Cephalothin 2 – 16  >16 
Chloramphenicol Chloramphenicol 2 – 64 >16 
Fluoroquinolone Ciprofloxacin 0.06 – 4 ≥4 
 Lomefloxacin 0.5 – 4  >4 
 Norfloxacin 4 – 8  >8 
 Ofloxacin 0.5 – 4  ≥4 
Glycopeptide Vancomycin 0.5 – 32  >16 
Ionophore Salinomycin 1 – 32 >8 b 
Lincosamide Clindamycin 0.25 – 2 >2 
 Lincomycin 1 – 32 NA c 
Macrolide Clarithromycin 0.12 – 4  >4 
 Erythromycin 0.12 – 32 >4 
 Tylosin 1 – 32 >8 b 
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Table 2. (Cont.) 
 
Penicillin Ampicillin 0.12 – 8 >8 
 Oxacillin 0.25 – 2  >2 
 Penicillin 0.03 – 32 >8 
Peptide Bacitracin d 8 – 256 >64 b 
Rifamycin Rifampin 0.5 – 2 >2 
Streptogramin Quinupristin-
dalfopristin 
0.5 – 32 ≥4 
 Virginiamycin 0.5 – 32 ≥4 b 
Tetracycline Tetracycline 0.25 – 32 >8 
Combination Ampicillin/ 
Sulbactam 
8/4 – 16/8  >16/8 
 Trimethoprim/ 
Sulfamethoxazole 
0.12/2.38 – 2/38 >2/38 
a All resistance breakpoints are those define by NCCLS unless otherwise noted (213). 
b Resistance breakpoints are those suggested for flavomycin and salinomycin (4) and 
tylosin and bacitracin (6). 
c NA, not applicable.  No interpretive criteria have been established. 
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Table 4. Distribution of Enterococcus spp. from the poultry production environment 
No. of isolates (% of total) 
Species identification All isolates 
(n = 532) 
Distinct isolates a 
(n = 331) 
E. avium 1 (0.2) 1 (0.3) 
E. casseliflavus 4 (0.8) 4 (1.2) 
E. durans 5 (0.9) 5 (1.5) 
E. faecalis 342 (64.2) 176 (53.2) 
E. faecium 127 (23.9) 104 (31.4) 
E. gallinarum 28 (5.3) 20 (6.0) 
E. hirae 16 (6.0) 13 (3.9) 
Group IIb 6 (1.1) 5 (1.5) 
Group IIIb 3 (0.6) 3 (0.9) 
a Isolates of the same species that came from the same farm were considered distinct if 
MICs to one or more antimicrobial differed by more than two dilutions. 
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Table 6.  Frequency of high-level aminoglycoside resistance patterns of Enterococcus 
spp. from the poultry production environment 
Frequency of resistance phenotype (% of species)a 
Species 
HLS HLK HLS+HLK HLK+HLG 
E. avium 0 0 0 0 
E. casseliflavus 1 (25) 0 1 (25) 0 
E. durans 1 (20) 1 (20) 0 0 
E. faecalis 62 (35) 15 (8.5) 5 (2.8) 13 (7.4) 
E. faecium 29 (28) 28 (27) 13 (13) 0 
E. gallinarum 7 (35) 1 (5.0) 1 (5.0) 0 
E. hirae 1 (7.7) 2 (15) 1 (7.7) 0 
Group IIb 1 (20) 0 0 0 
Group IIIb 2 (67) 0 0 0 
Total 104 (31) 47 (14) 21 (6.3) 13 (3.9) 
a Resistance breakpoints for Enterococcus spp. were >1000 µg/ml for high-level 
streptomycin (HLS), >500 µg/ml for high-level kanamycin (HLK), and high-level 
gentamicin (HLG). 




















Figure 5. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to flavomycin.  Of the E. faecalis isolates, 0%were resistant 
(MIC50 = 2 µg/ml, MIC90 = 2 µg/ml, mode = 2 µg/ml) and 100% of E. faecium isolates 
were resistant (MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, mode = >32 µg/ml).  Dashed 



















Figure 6. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to cefazolin.  Of the E. faecalis isolates, 94% were resistant 
(MIC50 = >16 µg/ml, MIC90 = >16 µg/ml, mode = > 16 µg/ml) and 98% of E. faecium 
isolates were resistant (MIC50 = >16 µg/ml, MIC90 = >16 µg/ml, mode = > 16µg/ml).  



















Figure 7. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to cephalothin.  Of the E. faecalis isolates, 98%were resistant 
(MIC50 = >16 µg/ml, MIC90 = >16 µg/ml, mode = >16 µg/ml) and 96% of E. faecium 
isolates were resistant (MIC50 = >16 µg/ml, MIC90 = >16 µg/ml, mode = >16 µg/ml).  




















 Figure 8. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to chloramphenicol.  Of the E. faecalis isolates, 0%were 
resistant (MIC50 = 8 µg/ml, MIC90 = 8 µg/ml, mode = 8 µg/ml) and 0% of E. faecium 
isolates were resistant (MIC50 = 8 µg/ml, MIC90 = 8 µg/ml, mode = 8 µg/ml).  Dashed 



















Figure 9. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to ciprofloxacin.  Of the E. faecalis isolates, 1.7% were resistant 
(MIC50 = 1 µg/ml, MIC90 = 2 µg/ml, mode = 1 µg/ml) and 52% of E. faecium isolates 
were resistant (MIC50 = 4 µg/ml, MIC90 = 4 µg/ml, mode = 4 µg/ml).  Dashed line 




















Figure 10. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to lomefloxacin.  Of the E. faecalis isolates, 31%were resistant 
(MIC50 = 4 µg/ml, MIC90 = >4 µg/ml, mode = 4 µg/ml) and 92% of E. faecium isolates 
were resistant (MIC50 = >4 µg/ml, MIC90 = >4µg/ml, mode = >4 µg/ml).  Dashed line 




















Figure 11. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to norfloxacin.  Of the E. faecalis isolates, 0%were resistant 
(MIC50 = ≤4 µg/ml, MIC90 = ≤4 µg/ml, mode = ≤4 µg/ml) and 2.9% of E. faecium 
isolates were resistant (MIC50 = ≤4 µg/ml, MIC90 = 8 µg/ml, mode = ≤4 µg/ml).  



















Figure 12. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to ofloxacin.  Of the E. faecalis isolates, 30.1% were resistant 
(MIC50 = 2 µg/ml, MIC90 = 4 µg/ml, mode = 2 µg/ml) and 96.2% of E. faecium isolates 
were resistant (MIC50 = >4 µg/ml, MIC90 = >4 µg/ml, mode = >4 µg/ml).  Dashed line 



















Figure 13. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to vancomycin.  Of the E. faecalis isolates, 0%were resistant 
(MIC50 = 1 µg/ml, MIC90 = 2 µg/ml, mode = 1 µg/ml) and 0% of E. faecium isolates 
were resistant (MIC50 = 1 µg/ml, MIC90 = 1 µg/ml, mode = 1 µg/ml).  Dashed line 



















Figure 14. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to salinomycin.  Of the E. faecalis isolates, 0% were resistant 
(MIC50 = 4 µg/ml, MIC90 = 4 µg/ml, mode = 4 µg/ml) and 0% of E. faecium isolates 
were resistant (MIC50 = 4 µg/ml, MIC90 = 8 µg/ml, mode = 4 µg/ml).  Dashed line 



















Figure 15. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to clindamycin.  Of the E. faecalis isolates, 100% were resistant 
(MIC50 = >2 µg/ml, MIC90 = >2 µg/ml, mode = >2 µg/ml) and 84% of E. faecium 
isolates were resistant (MIC50 = >2 µg/ml, MIC90 = >2 µg/ml, mode = >2 µg/ml).  



















Figure 16. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to lincomycin.  Of the E. faecalis isolates, 88% were resistant 
(MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, mode = >32 µg/ml) and 89% of E. faecium 
isolates were resistant (MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, mode = >32 µg/ml) at 




















Figure 17. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to clarithromycin.  Of the E. faecalis isolates, 67% were 
resistant (MIC50 = >4 µg/ml, MIC90 = >4 µg/ml, modes = 1 and >4 µg/ml) and 24% of 
E. faecium isolates were resistant (MIC50 = 0.5 µg/ml, MIC90 = >4 µg/ml, modes = 
≤0.12 and >4 µg/ml).  Dashed line denotes the NCCLS-defined breakpoint for resistance 




















Figure 18. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to erythromycin.  Of the E. faecalis isolates, 69%were resistant 
(MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, modes = 1 and >32 µg/ml) and 34% of E. 
faecium isolates were resistant (MIC50 = 1 µg/ml, MIC90 = >32 µg/ml, modes = ≤0.12, 
1, 8, and >32 µg/ml).  Dashed line denotes the NCCLS-defined breakpoint for resistance 




















Figure 19. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to tylosin.  Of the E. faecalis isolates, 69% were resistant 
(MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, modes = 2 and >32 µg/ml) and 13.5% of E. 
faecium isolates were resistant (MIC50 = 4 µg/ml, MIC90 = >32 µg/ml, modes = 4 and 




















Figure 20. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to ampicillin.  Of the E. faecalis isolates, 0% were resistant 
(MIC50 = 1 µg/ml, MIC90 = 2 µg/ml, mode = 1 µg/ml) and 1% of E. faecium isolates 
were resistant (MIC50 = 8 µg/ml, MIC90 = 8 µg/ml, mode = 8 µg/ml).  Dashed line 



















Figure 21. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to oxacillin.  Of the E. faecalis isolates, 100% were resistant 
(MIC50 = >2 µg/ml, MIC90 = >2 µg/ml, mode = >2 µg/ml) and 98% of E. faecium 
isolates were resistant (MIC50 = >2 µg/ml, MIC90 = >2 µg/ml, mode = >2 µg/ml).  

























 Figure 22. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to penicillin.  Of the E. faecalis isolates, 0% were resistant 
(MIC50 = 2 µg/ml, MIC90 = 4 µg/ml, mode = 2 µg/ml) and 71% of E. faecium isolates 
were resistant (MIC50 = 16 µg/ml, MIC90 = 32 µg/ml, mode = 32 µg/ml).  Dashed line 



















Figure 23. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to bacitracin.   Of the E. faecalis isolates, 93% were resistant 
(MIC50 = >256 IU/ml, MIC90 = >256 IU/ml, modes = 64 and >256 IU/ml) and 100% of 
E. faecium isolates were resistant (MIC50 = >256 IU/ml, MIC90 = >256 IU/ml, mode = 
>256 IU/ml).  Dashed line denotes the defined breakpoint for resistance (>64 IU/ml) (6).  



















Figure 24. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to rifampin.  Of the E. faecalis isolates, 10.2% were resistant 
(MIC50 = 1 µg/ml, MIC90 = >2 µg/ml, mode = 1 µg/ml) and 2.9% of E. faecium isolates 
were resistant (MIC50 = ≤0.5 µg/ml, MIC90 = ≤0.5 µg/ml, mode = ≤0.5 µg/ml).  Dashed 





















Figure 25. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to quinupristin-dalfopristin.  Of the E. faecalis isolates, 96% 
were resistant (MIC50 = 8 µg/ml, MIC90 = 8 µg/ml, mode = 8 µg/ml) and 64% of E. 
faecium isolates were resistant (MIC50 = 8 µg/ml, MIC90 = 32 µg/ml, modes = 2 and 16 






















Figure 26. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to virginiamycin.  Of the E. faecalis isolates, 96% were resistant 
(MIC50 = 8 µg/ml, MIC90 = 16 µg/ml, mode = 8 µg/ml) and 64% of E. faecium isolates 
were resistant (MIC50 = 8 µg/ml, MIC90 = 32 µg/ml, modes = 1, 16, and 32 µg/ml).  



















Figure 27. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to tetracycline.  Of the E. faecalis isolates, 91% were resistant 
(MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, modes = 1 and >32 µg/ml) and 79% of E. 
faecium isolates were resistant (MIC50 = >32 µg/ml, MIC90 = >32 µg/ml, modes = 0.5 




















Figure 28. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to ampicillin/sulbactam.  Of the E. faecalis isolates, 0% were 
resistant (MIC50 = ≤8/4 µg/ml, MIC90 = ≤8/4 µg/ml, mode = ≤8/4 µg/ml) and 0% of E. 
faecium isolates were resistant (MIC50 = ≤8/4 µg/ml, MIC90 = ≤8/4 µg/ml, mode = ≤8/4 




















Figure 29. Susceptibility profiles of E. faecalis and E. faecium from the poultry 
production environment to trimethoprim/sulfamethoxazole.  Of the E. faecalis isolates, 
0.6% were resistant (MIC50 = ≤0.12/2.38 µg/ml, MIC90 = 0.5/9.5 µg/ml, modes = 
≤0.12/2.38 and 0.5/9.5 µg/ml) and 0% of E. faecium isolates were resistant (MIC50 = 
≤0.12/2.38 µg/ml, MIC90 = 0.5/9.5 µg/ml, modes = ≤0.12/2.38 and 0.5/9.5 µg/ml).  




Characterization of the Macrolide-Lincosamide-Streptogramin Resistance 




 The impact of agricultural use of antimicrobials on the future efficacy of 
therapeutic drugs in human medicine is a growing public concern.  Quinupristin-
dalfopristin (Q-D) has been approved to treat human disease due to vancomycin-resistant 
Enterococcus faecium and is related to virginiamycin, a streptogramin that has long been 
used in U.S. agriculture poultry production.  The magnitude of transferable resistance 
elements selected by the agricultural use of streptogramin antimicrobials is largely 
unquantified within the poultry production environment of the U.S.   
Streptogramin-resistant isolates of E. faecium from poultry production 
environments from the eastern seaboard were recovered without selection for 
streptogramin resistance and subjected to ribotyping to evaluate clonal bias.  Colony PCR 
screening for the streptogramin resistance determinants erm(A), erm(B), msr(C), mef(A), 
lnu(B), vgb(A), vat(D), and vat(E) was performed to determine the prevalence of 
previously described macrolide-lincosamide-streptogramin (MLS) resistance 
mechanisms.   
The collection of E. faecium were unevenly distributed among 28 ribogroups that 
did not represent geographic clustering.  The most prevalent ribogroups were composed 
of isolates that possessed diverse antimicrobial resistance profiles.  Of these 127 isolates, 
63% were Q-D-resistant.  The resistance determinants erm(A), erm(B), and mef(A) were 
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observed among 15%, 30%, and 11%, respectively, of macrolide-resistant isolates.  
Msr(C) was isolated in a single isolate that was resistant to macrolide and lincosamide 
antimicrobials.  The streptogramin B hydolase vgb(A) and the streptogramin A 
acetyltransferases genes vat(D) and vat(E) were not detected in any of the E. faecium 
isolates.  These results indicate that resistance to MLS antimicrobials is widespread 
among E. faecium from the poultry production environment and that the mechanisms of 




Enterococci, particularly E. faecalis and E. faecium, present serious challenges to 
the control of antimicrobial resistance as they are the third leading cause of nosocomial 
infections in intensive care units in the United States (44).  In addition, they are known to 
be intrinsically resistant to several antibiotics and perhaps more importantly, are adept in 
acquiring and transferring elements that confer resistance to antimicrobials.  As a result, 
therapeutic options are increasingly limited for the treatment of enterococcal infections 
(205).   
In 1980 the reported development and subsequent increase in resistance to the 
glycopeptide vancomycin among clinical isolates of Enterococcus spp. was followed by a 
flurry of research into new antimicrobials for alternative therapy.  The 1999 Food and 
Drug Administration approval of the streptogramin, quinupristin-dalfopristin (Q-D or 
Synercid®), to treat vancomycin-resistant E. faecium infections came after more than 20 
years of widespread use of a streptogramin analogue, virginiamycin, in animal production 
in the U.S.  This has revived concerns that use of antimicrobials in food animal 
production might compromise the efficacy of related drugs in human clinical medicine 
through selection of resistant populations and their subsequent transfer through the food 
supply (112). 
Previous work has demonstrated that single resistance elements can confer 
resistance to macrolide-lincosamide-streptogramin B (MLSB) antimicrobials whereas 
resistance to a streptogramin combination requires resistance to both A and B 
components (35).  We have previously described the frequent occurrence of 
streptogramin resistance among E. faecium from a poultry production environment of the 
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U.S. (124), likely due to the continued use of macrolide and lincosamide antimicrobials, 
specifically tylosin and lincomycin, as well as the streptogramin virginiamycin.  This 
work describes the diversity and genetic mechanisms that contribute to the prevalence of 
MLS resistance phenotypes among E. faecium from the poultry production environment 
of a geographically defined region of the U.S. that is an area of intensive poultry 
production. 
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MATERIALS AND METHODS 
Ribotyping of Enterococcus faecium isolates.  Automated ribotyping of the 127 
isolates of E. faecium was accomplished using the RiboPrinter® microbial 
characterization system (Dupont Qualicon United States, Wilmington, DE) performed 
under the conditions recommended by the manufacturer of as described previously 
(Figure 30) (38). In brief, this automated process included the lysis of a bacterial cell 
suspension through the use of a ten minute heat treatment at 80oC and lysis reagents.  The 
extracted DNA was then cleaved by the activity of the restriction endonuclease EcoRI.  
DNA fragments were separated by size using electrophoresis through a 1% agarose gel 
and transferred to a moving nylon membrane by direct blot electrophoresis.  The DNA 
fragments were then hybridized with a labeled rRNA operon probe derived from 
Escherichia coli, washed and treated with blocking buffer and an antisulfonated DNA 
antibody/alkaline phosphatase conjugate. Unbound conjugate was removed and the bands 
were detected using a chemiluminescent substrate.  An image was captured using a 
customized charge-coupled device camera and was then electronically transferred to the 
system's computer. The analysis software uses the position and intensity of the five well 
characterized marker fragments (1, 3.2, 6.5, 9.6, and 48 kb), which were run alongside 
the samples, to normalize the resulting output data. The positions of these standard 
marker bands are used to correct for lane to lane and membrane-to-membrane variations 
in band position.  In addition, the following ATCC quality control organisms were run 
with every fifth batch:  E. coli 51739, S. aureus 51740, Salmonella ser. Infantis 51741, 
and Listeria innocua 51742. 
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Cluster Analysis.  Normalized patterns were imported into the Bionumerics 
version 3.0 software (Applied Maths) using an import script provided by DuPont 
Qualicon.  Band analysis was performed following an automatic band search by using the 
following parameters: minimum profiling parameter of 3.0% and gray zone parameter of 
0% relative to the maximal value, a minimum area parameter of 0%, and a shoulder 
sensitivity parameter of zero.  Clustering was performed by using the unweighted pair 
group method with average (UPGMA) based on the Dice similarity index with a 1.5% 
band position tolerance and 1.5% optimization coefficient to determine isolate similarity.  
 
Preparation of DNA from Enterococcus faecium isolates.  DNA template was 
prepared by boiling 4-5 colonies in 200 µl of sterile water for ten minutes in MicroAmp® 
96-well plates (Applied Biosystems, Foster City, CA).  Plates were centrifuged at 2500 
rpm for three minutes in a Centra®-CL3 centrifuge (Thermo IEC, Needham Heights, 
MA) and the supernatant was transferred to another plate for storage at -20oC.   
Alternative means of DNA isolation were employed when positive control PCR 
reactions did not result in amplification of product.  The method of Vakulenko et al. 
involved the emulsification of 3-5 colonies in 25 µl of a 0.25% sodium-docecyl-
sulfate/0.05 N NaOH solution (296).  The suspension was then boiled in a water bath for 
15 minutes and 200 µl of deionized water were added to generate a working stock of 
template DNA.  The method of De Azavedo involved suspending a loopful of overnight 
bacterial growth taken from sheep blood agar in 100 µl of a lysis buffer (100 mM NaCl, 
10 mM Tris HCl [pH 8.0], 1% Triton X-100) and boiling for 10 minutes (67).  The 
suspension was then centrifuged briefly and the supernatant was used as template. 
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PCR screening for MLS resistance determinants.  Ten microliters of template 
DNA was used in all PCR reactions.  All PCR reactions were carried out using a 96-well 
GeneAmp® PCR System 9700 thermocycler (Applied Biosystems) in a 50 µl volume.  
Fifty pmol of each primer were used in resistance screening and are listed in Table 7.  
Primer sequences for msr(C), mef(A), and vgb(A) were determined using the Vector 
NTI™ software package (Informax, Frederick, MD).  Two primer sets were used for the 
lnu(B) PCR reactions; lnuB1, 5’-GCA AAT GGT GTA GGT AAG ACA ACT-3’ and 
lnuB2, 5’-ATC ATG TGA TGT AAA CAA AAT-3’ as published previously (270); 
linB1, 5’- GCA AAC GTT AAG AAT CTT AC-3’ and linB2 5’-GCA TTT TCT TCA 
GTA AGT CT-3’ were determined using the Vector NTI™ software of the GenBank 
accession AJ238249 (34). 
PCR reactions for each of the previously described streptogramin resistance 
determinants [erm(A), erm(B), msr(C), vgb(A), vat(D), and vat(E)] as well as the E. 
faecium-specific gene D-alanine:D-alanine ligase (ddl) was carried out using AmpliTaq 
Gold ® (Applied Biosystems) according to the manufacturer’s suggestions.  The PCR 
conditions used for each reaction are listed in Table 8.  PCR screening was performed in 
triplicate among all isolates that produced an amplicon and among an equal number of 
PCR-negative isolates. 
PCR reactions were visualized using the 2% agarose E-Gel® 96 High-Throughput 
Agarose Electrophoresis System (Invitrogen, Carlsbad, CA).  Positive control strains are 
listed in Table 9.  E. faecium TX1330 SE34 was kindly provided by Dr. B. Murray, E. 
faecalis JH2-2/1025 and E. coli DH10B/pVMM25 from Dr. R. Leclercq, S. aureus 
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BM3093/pIP680 from Dr. N. El Solh, and Group B Streptococcus R132 from Dr. J. de 
Azavedo.  Additional CVM control strains were provided by Dr. S. Simjee. 
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RESULTS 
 Diversity and dispersion of Enterococcus faecium isolates from the Delmarva 
Peninsula.  The collection of 127 E. faecium from the poultry production environment 
was distributed among 28 distinct ribogroups (Figure 31).  Five of the isolates did not 
generate a ribotype pattern despite repeated testing.  Sixteen ribotypes were rarely 
encountered and were represented by single isolates of E. faecium.  Interestingly, a single 
ribotype was observed among 33% of the isolates whereas the four most prevalent 
ribotypes constituted 82/127 (65%) of the observed population, but displayed 
inconsonant antibiograms within each ribotype.   
 The geographical distribution of the encountered ribotypes of E. faecium isolates 
is presented in Figure 32.  E. faecium was not isolated from twelve sampled farms and a 
farm location was not provided for 26 (20%) of the recovered isolates.  The greatest 
diversity of ribotype patterns from a given region was directly related to the number of 
farms sampled.   
Analysis of the geographic distribution of E. faecium ribogroups was confounded 
by the predominance of three ribogroups and the infrequent observation of a majority of 
other ribogroups.  The four most prevalent ribogroups were observed to be widely 
distributed across the sampling region with no obvious clustering.   
 
Geographic dispersion of MLS phenotypes of E. faecium from the Delmarva 
Peninsula.  Phenotypic resistance to MLS antimicrobials was heterogeneous among the 
E. faecium isolated.  The most prevalent phenotype observed was resistance to 
lincosamide and streptogramin antimicrobials (47%) (Table 10).  Macrolide-lincosamide-
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streptogramin resistance was observed among 17% of isolates as well as resistance to 
macrolide and lincosamide antimicrobials and isolated lincosamide resistance.  Four 
isolates (3%) were observed to possess resistance to macrolide antimicrobials and a 
single isolate (0.8%) was sensitive to all MLS antimicrobials.  Whereas increased 
tolerance to lincomycin was observed independent of resistance to other antimicrobials, 
only a small percentage of isolates were resistant to macrolide antimicrobials and no 
isolates were observed to be resistant to streptogramin antimicrobials in the absence of 
macrolide or lincosamide resistance. 
Many diverse MLS phenotypes were observed across the sampled region (Figure 
33).  Lincosamide resistance was observed to be a nearly ubiquitous trait among the 
isolates as well as geographically over the sampled region.  This phenotype was observed 
to be frequently accompanied by resistance to streptogramin antimicrobials in the 
absence of resistance to macrolides.  Isolates that were observed to be resistant to 
macrolide, lincosamide, and streptogramin antimicrobials were somewhat concentrated in 
the interior of the sampled region, most often from areas that were heavily surveyed.  
Within this region, however, isolates were also recovered that were not observed to be 
resistant to more than a single antimicrobial.  It is important to note that the analysis of 
the geographic dispersion of MLS phenotypes among isolated E. faecium suffers the 
same limitations as the previously mentioned ribogroup pattern analysis, i.e., the lack of 
isolation of E. faecium from twelve sampled farms and no farm location for 26 (20%) of 
the recovered isolates.   
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 Distribution of MLS resistance elements among E. faecium.  PCR screening 
for MLS resistance determinants revealed the presence of the rRNA methylase genes 
erm(A) and erm(B) in 6.3 and 14.2% of all isolates (Table 10).  The prevalences of the 
individual genes were predictably highest among macrolide-resistant isolates of with 15% 
with erm(A) and 30% with erm(B).  The mef(A) gene was detected among 5% and the 
msr(C) gene in 1% of all isolates.  Of particular interest was the detection of erm(A), 
erm(B), and mef(A) among isolates that were not phenotypically resistant to macrolide 
antimicrobials.  Additionally, no macrolide resistance element was detected among 23/46 
isolates that were phenotypically resistant to macrolides. 
Resistance to streptogramin antimicrobials was largely unaccounted for by PCR 
screening for specific resistance determinants.  The genes vgb(A), vat(D), and vat(E) 
were not detected among the collection of E. faecium isolates.  The genes erm(A) and 
erm(B) were detected in only 6% and 10%, respectively, of isolates phenotypically 
resistant to streptogramins. 
Detection of the gene lnu(B) was not possible due to negative PCR reactions from 
three different control strains.  The use of two alternative methods of preparing template 




Although enterococci from the food animal production environment have not 
been conclusively linked as direct causes of clinical infections, the potential risk of the 
agricultural usage of antimicrobials in food animal production is increasingly an issue of 
public concern.  Of the numerous methods currently employed to type bacterial 
collections, pulsed-field gel electrophoresis (PFGE) is considered the “gold-standard” 
typing method for E. faecium of clinical origin (190).  Newer methods that have been 
employed in this fashion also include amplified fragment length polymorphism (AFLP) 
and multilocus sequence typing (MLST) analysis (14,128,324).  Most typing methods 
suffer from the dual limitations of a lack of standardization and the need for a significant 
amount of skilled personnel time.  The application of automated rRNA gene restriction 
fragment analysis, or ribotyping, is a highly reproducible method for clonal analysis.  
Because rRNA operons are the most highly conserved region of the bacterial genome, 
ribotyping offers the advantage of eliminating most variability and has been previously 
applied in studies of E. faecium from a variety of environments (37,116).   
Although ribotyping has been previously described as a less discriminatory tool 
than PFGE, it offers the advantages of facility, speed, and standardization (116).  
Additionally, ribotyping has been demonstrated to be as capable as PFGE of detecting 
identical “types” of vancomycin-resistant E. faecium of human and animal origin in 
Denmark (116).  Despite the comparatively reduced “power” of ribotyping, the method 
has been shown to discriminate between strains of E. faecium that were considered 
identical by AFLP typing and/or MLST (37). 
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The results of this study suggest that common lineages of E. faecium can be 
isolated from poultry production environments that are geographically widely distributed.  
Whereas several ribogroup clusters were predominant, the analysis indicates that many 
less common sub-populations can also be observed.  These observations are supported by 
other studies which illustrate the diversity of enterococcal populations within distinct 
environments (158,299,302,313). 
The relative predominance of increased tolerance of isolates of E. faecium to 
lincosamide antimicrobials that we have observed has been similarly described in studies 
of human (75) and animal production environments (4).  Given the use of the analog 
virginiamycin in food animal production environments in the U.S. since 1974, resistance 
to quinupristin-dalfopristin among E. faecium of poultry origin is not surprising 
(124,313).  Our observations of the magnitude of resistance are generally comparable to 
those of poultry origin from Denmark (2,6), however our observation of macrolide 
resistance among 36% of E. faecium is much lower than previous reported observations 
from Denmark and Japan (2,329). 
The heterogeneous nature of MLS resistance phenotypes observed among E. 
faecium belonging to a distinct ribogroup pattern suggests that acquisition of resistance to 
these antimicrobials is dynamic.  Despite the long-term approval and presumed industrial 
usage of MLS antimicrobials in this region, this diversity is quite striking.  Whereas the 
decreased use of these antimicrobials during production has been shown to parallel the 
drop in the prevalence of resistance to MLS antimicrobials among E. faecium (7), other 
factors may help to explain the absence of uniform resistance to all MLS antimicrobials.  
The regular entry of a sizeable population of susceptible E. faecium into the poultry 
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production environment from sources such as feed commodities and the natural flora of 
incoming flocks of unmedicated chickens are likely sources.  Resistant populations may 
be present at an undetectable density due to the comparative sizes of resistant and 
susceptible populations and may preclude the observation of phenotypic resistance 
through the use of a non-selective cultural method.  In this situation, the small, resistant 
population of E. faecium may persist in the production environment until such time that it 
is selectively amplified by the use of MLS antimicrobials, whereupon MLS-resistant E. 
faecium could rapidly become predominant.   
Alternative selective pressure may be applied through the periodic use of other 
antimicrobials that do not select for MLS-resistant isolates, which would lead to a 
decreased prevalence of observed resistance.  A recent prospective study in Denmark 
suggests that other environmental influences may also affect the dynamics of MLS 
resistance in the animal production environment.  In that study, researchers demonstrated 
that the use of copper sulfate may co-select for antimicrobial resistance in animal 
production, with the strongest interactions in production environments that heavily use 
the additive (122).   
The relative prevalence of previously described rRNA methylases that confer 
resistance to macrolide, lincosamide, and streptogramin B antimicrobials among E. 
faecium from this study was conserved, but the frequency differed.  The prevalence of 
erm(A) among macrolide-resistant isolates of E. faecium seen in this study (15%) is 
somewhat larger than that observed in previous studies.  Estimates of erm(A) prevalence 
among macrolide-resistant isolates reveal that it is infrequent (229) with an observed 
prevalence of 1% of poultry and porcine isolates from Denmark, Finland, and Norway (6) 
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and 5% of EU clinical isolates (258).  The prevalence is similar to that reported in 
streptogramin-resistant enterococcal isolates from Danish poultry (138). 
The results from this study differ markedly from the prevalence of erm(B) in the 
EU which is estimated to be up to 88% of macrolide-resistant isolates of poultry and 
porcine origin (5,6).  The high prevalence of erm(B) is similarly observed among clinical 
isolates resistant to macrolides from European countries (229,258).  Analogous to the 
situation with erm(A), the prevalence of erm(B) is similar among streptogramin-resistant 
isolates from Danish poultry and pigs (138), as well as those of clinical origin (35,273).  
Less resistance was observed in a U.S. study of retail poultry products in which erm(B) 
was observed in 41% of streptogramin-resistant isolates (267).   
The prevalence of the efflux pump mef(A), estimated as high as 22% of U.S. 
clinical isolates of Enterococcus spp. (176), is in sharp contrast to with the absence of 
mef(A) among enterococci isolated from Belgian pork production environments (183).  A 
mef-like gene has been observed in a single clinical isolate from Spain (229).  The 
observation that most of the infrequently-encountered mef(A)-positive isolates in this 
study were not phenotypically resistant to macrolide antimicrobials suggests that the gene 
may not be constitutively expressed. 
The msr(C) gene was initially described among clinical isolates of E. faecium as a 
likely intrinsic feature of the species (229).  Subsequent studies of msr(C) confirmed the 
previous observation that msr(C) was conserved among E. faecium of clinical origin 
(270).  The gene contributed to a rise in erythromycin MIC by six-fold, but was not solely 
responsible for macrolide resistance.  The gene also did not markedly affect the MIC for 
lincosamide antimicrobials (270).  A study of E. faecium from multiple sources in 
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Germany revealed that the msr(C) gene could not be detected in 42% of isolates (315) 
with a subsequent study indicating its absence in 31% of isolates from poultry (316).  The 
results of the present study (0.8%), in contrast, suggest that the gene is infrequent among 
isolates from U.S. poultry production environments. 
The nucleotidyltransferase lnu(B) [previously known as lin(B)] was initially 
described in a clinical isolate of E. faecium from France.  This genetic element was 
demonstrated to be on a 240-kb plasmid and parenthetically described as present among 
all 14 isolates of E. faecium of clinical origin that inactivated lincosamides (34).  In the 
time since the publication of this observation, lnu(B) has been described in only a single, 
lincosamide-resistant isolate of group B Streptococcus of clinical origin from Canada 
(66).  The inability to amplify this gene from isolates received by either research group 
despite exhaustive efforts precludes a description of its frequency among isolates from 
this study.  Future research will hopefully shed light on the validity of these observations. 
The initial description of the streptogramin B hydrolase vgb(A) among 
enterococci was in a clinical isolate of streptogramin-resistant E. faecium from The 
Netherlands (137).  Since its description, it has been identified in only one other instance; 
a clinical isolate from France (36).  Its absence among isolates in this study is consistent 
with previous studies that indicate the rarity of this gene among E. faecium from diverse 
environmental sources (138,241,267,315,317). 
Known resistance elements that confer streptogramin A resistance to E. faecium 
include the acetyltransferases encoded by the genes vat(D) and vat(E).  The prevalence of 
vat(D) among isolates of poultry origin from Europe is estimated between 10 to 13% 
(6,138).  The gene has not been detected in a recent survey of resistant isolates from U.S. 
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retail poultry (267), which is consistent with the results of this study.  Among resistant 
isolates from pigs in European production operations, vat(D) has been found among 2-
7% of isolates (5,6,138).  Comparative studies suggest that in addition to its more 
frequent isolation from pigs, vat(D) also is found more frequently among isolates of 
human origin (137,273,317).  A survey of clinical isolates from Spain, however, suggests 
that the predominant resistance mechanism may vary by region (241). 
Vat(E) has been observed to be more frequently encountered among isolates of 
poultry origin and accounts for 72 to 100% of streptogramin-resistant poultry isolates 
from Europe (6,120,138,317).  In contrast, vat(E) is estimated to be present among only 4 
to 7% of resistant-isolates from pigs (5,138).  Among resistant isolates from U.S. retail 
poultry, vat(E) was observed in 37% of resistant isolates (267).   
The absence of streptogramin A resistance elements previously described among 
isolates of E. faecium has been observed previously.  A UK study revealed that neither 
vat(D) nor vat(E) could be amplified from streptogramin-resistant isolates from humans 
and seawater (274).  This was similarly observed among resistant isolates from healthy 
and hospitalized subjects from the U.S (75) and clinical isolates from France (35).  
Unidentified mechanisms are also thought to be present in 3 to 29% of isolates from 
different ecological origins (138,273,317) and 86% of isolates from Danish pigs (138).   
Whereas the negative screening results from this study for known 
acetyltransferases does not exclude the possibility that other acetyltransferases may exist 
in this collection of E. faecium, other studies do not support the contention of 
acetyltransferase genes similar in sequence to vat(D) and vat(E) (273).  This work did not 
examine the possibility that the ATP-binding cassette transporter mechanisms that can 
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confer streptogramin A resistance in staphylococci by active efflux [vga(A) and vga(B)] 
may be present in these isolates (10,11).  Previous surveys of resistance mechanisms 
among streptogramin-resistant E. faecium that have sought to identify these mechanisms 
have not proven successful (35,267,273). 
The seminal work by Bozdogan and Leclercq suggests that in an isolate resistant 
to lincosamide and streptogramin A components by an unknown mechanism can be 
conferred resistance by complementation with streptogramin B [vgb(A)] streptogramin A 
[vat(D)] resistance elements (35).  It is noteworthy that the quinupristin-dalfopristin MIC 
was unaffected when this strain was complemented with the MLSb resistance 
determinant erm(B).  In the case of complementation studies with the vgb(A), the 
mechanism is straightforward.  Complementation studies with the acetyltransferase 
vat(D), however, would suggest that the Vat(D) enzyme, in the presence of an 
unidentified mechanism, might have some measure of activity against streptogramin B 
antimicrobials (35).  Although the original description of vat(D) in E. faecium illustrates 
the high activity of the product against streptogramin A components, the enzyme was 
also characterized as having a broader spectrum of activity (236).   
The recent observations of vancomycin resistance elements of enterococcal origin 
in U.S. clinical isolates of S. aureus suggest that alternative therapies, such as linezolid 
and Q-D, will be more frequently employed (45,46).  Resistance to linezolid has already 
been observed (16,21,111,139,209,247) and at least in one case without prior exposure 
(140) which raises concerns about the long-term efficacy of alternatives to antimicrobial 
chemotherapy.  The resistance elements for vancomycin and streptogramin resistance 
have been reported to be co-localized on the same plasmid of clinical isolates from 
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France and Germany (36,318).  It is troubling that in at least one study that these resistant 
strains have been found to be genetically identical to susceptible strains that are endemic 
in the hospital environment and have spread similarly (128,318), possibly due to the 
documented in vivo transfer of resistance in the mammalian gastrointestinal tract (117).   
Current estimates of Q-D resistance among E. faecium in the U.S. community 
(75,186) do not currently mirror the European experience of the vancomycin-analogue 
avoparcin in food animal production establishing a base of resistance in the community 
(107,127,156,157,260,279,299,300).  That small population, however, may be amplified 
as a result of an increase in selective pressure in the clinical environment.   
Although existing evidence does not suggest that enterococci of foodborne origin 
should be regarded as bacterial pathogens, they could serve as potential reservoirs of 
virulence and antimicrobial resistance genes to host-adapted strains.  The observations of 
this study suggest that resistant isolates of Enterococcus faecium are commonly found 
within poultry production environments and ostensibly, can contaminate retail meat 
products.  Effective control strategies aimed at reducing the size of the resistant 
population to which consumers are exposed may become even more significant in the 
future with the potential increase in the frequency of resistant isolates as human 
opportunistic pathogens. 
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Table 7. Primer sequences used for resistance screening 












































Table 8. PCR reactions used for resistance screening 

























































































































Table 9. Control strains used for resistance screening 
Control Strain Gene a Source 
E. faecium CVM3480 erm(A) Retail chicken rinse 
E. faecium CVM3002 erm(B), vat(E) Human stool 
E. faecium TX1330 SE34 msr(C) Human clinical 
E. coli Sp970264/pMR970 mef(A) Human clinical b 
S. aureus BM3093/pIP680 vgb(A) Human clinical 
E. faecalis JH2-2/1025 
E. coli DH10B/pVMM25 




Human clinical c 
Human clinical c 
Human clinical 
E. faecium CVM3001 vat(D) Human stool 
E. faecium CVM3475 erm(A), vat(E) Retail Chicken Rinse 
E. faecium CVM3976 erm(B) Retail Chicken Rinse 
E. faecium CVM4761 erm(B), msr(C) Human stool – hospitalized patient 
E. faecium CVM18769 msr(C) Human stool 
a The presence of all indicated genes was confirmed with PCR with the exception of 
lnu(B) positive control organisms. 
b Transconjugant of original strain Enterococcus spp. 102. 
c Transconjugant of original strain Enterococcus faecium HM1025. 
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Figure 32. Dispersion of ribogroups of E. faecium among sampled commercial poultry 
houses on the Delmarva Peninsula 
 




Figure 33. Dispersion of MLS resistance phenotypes of E. faecium among sampled 
commercial poultry houses on the Delmarva Peninsula 
 



















































































































































































































































































































































































































































































































































The clinical significance of enterococci is sometimes difficult to interpret 
because, in this setting, they are often part of a mixed microbiota in a number of 
pathologic conditions, and often, they are considered contaminants rather than true 
pathogens.  However, the increased prevalence of nosocomial urinary tract infections and 
bacteremia in recent times has clearly demonstrated that these organisms are 
unmistakably pathogenic in these environments.  The most important clinical feature of 
enterococcal infections is the high prevalence of resistance to numerous antimicrobials.  
Enterococci are known to be intrinsically resistant or tolerant to many antimicrobials, 
with E. faecium more often resistant than E. faecalis (193,286).  Resistance to high-level 
aminoglycosides in the 1970s was soon followed by resistance to β-lactam 
antimicrobials, narrowing the therapeutic choices for treating enterococcal infections.  
This restriction of treatment options resulted in the increased and frequently unnecessary 
reliance upon the vanguard of formulary, the glycopeptide vancomycin.  The initial 
description of vancomycin-resistant enterococci (VRE) infections in 1986 was followed 
by a twenty-fold increase in VRE infections from 1989 to 1993 in the U.S. (43).  
Currently VRE constitute 26% of nosocomial enterococcal isolates from U.S. intensive 
care units (44).   
Whereas the transmission of enterococci in the clinical environment stems from 
fecal contamination of hospital surfaces, the most common vehicle of exposure of healthy 
persons is thought to be the consumption of contaminated food.  Increased concern about 
the continued efficacy of current antimicrobials has led to a tremendous amount of 
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interest in the impact of the use of antimicrobials in food animal production on the future 
efficacy of treating enterococcal infections.  One of the major limitations in assessing the 
risk of enterococci from food animals has been the understanding the species diversity 
present in production and processing environments.  Among these species, the magnitude 
of antimicrobial resistance to drugs used in agriculture and clinical environments in 
Enterococcus spp. in the U.S. is largely unknown.  Whereas few studies have estimated 
the degree of resistance beyond a single farm, it is critically important to sample a wider 
geographic area in an attempt to evaluate the prevalence of resistance.  Public concern 
over the use of the streptogramin antimicrobial virginiamycin in poultry and other food 
animal production environments following the approval of quinupristin-dalfopristin to 
treat resistant human E. faecium infections underscores the importance in understanding 
the genetic background behind the phenotypic resistance observed to MLS 
antimicrobials.   
The first area of study in this dissertation focused on the isolation and 
identification of Enterococcus spp. from the poultry production and processing 
environments.  Using an experimental medium designed to isolate staphylococci as well 
as enterococci, isolates were successfully recovered from poultry environments on the 
Delmarva Peninsula.  This work demonstrated that a more selective protocol would 
reduce the amount of time and resources spent working on non-enterococcal isolates as 
well as increasing the successful yield of enterococci from collected samples.  Previous 
work has suggested that a resuscitation step in the isolation procedure followed by the use 
of an elevated incubation temperature may improve the recovery of stressed or injured 
enterococci from the environment (92).  This modification would improve the recovery 
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of enterococci from diverse environmental samples through the suppression of other 
resident microflora.  One disadvantage to this application is that despite the description of 
members of Enterococcus spp. as being able to grow at temperatures of 45oC, such 
thermotolerance may not be a consistent trait among all species of enterococci, especially 
in combination with a stressful selective medium.  Both observations have been observed 
in preparatory studies conducted at the U.S. FDA Center for Veterinary Medicine, Laurel, 
MD.  A recent survey has demonstrated that the incorporation of these changes in 
isolation procedures demonstrates the nearly ubiquitous distribution of enterococci from 
retail meat products (123).  This work has detailed the similar presence of Enterococcus 
spp. from the production and processing environments across a wide geographic area.  
One proven disadvantage of the drive to develop methods to quickly screen for unique 
enterococci is that the species diversity from a given sample may be underestimated.  
Following growth on a solid selective medium, bacterial colonies that appear to be 
homogeneous may, after further incubation for up to 72h at room temperature, develop 
distinctive colonial morphotypes (231).  This modification has also been demonstrated to 
have clinical relevance as up to 15% of VRE may be unrecognized with a shorter term of 
incubation (248). 
Essential to the characterization of isolates was the adaptation of a biochemical 
methodology for identification of Enterococcus to the species level.  This test was 
demonstrated to be equally capable as traditional biochemical assays, utilizing the most 
discriminatory assays of carbohydrate and amino acid utilization.  This had the effect of 
reducing the total number of biochemical assays needed to achieve reasonable certainty 
of identification based on the knowledge of current species.  The relative prevalence of 
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Enterococcus spp. described in this work confirms observations made in other countries 
as well as limited studies that have been conducted in the U.S.  The predominance of E. 
faecalis and E. faecium species of the enterococcal microflora from poultry production 
and processing environments described in this work are notably the same species that are 
responsible for most enterococcal disease in humans.   
Since the conclusion of this phase of the project, a number of new species of 
enterococci have been described.  Given the similarity of these newly described species 
to more well-known members of the genus, confident identification to the species level 
may be questionable without confirmatory molecular screening (71).  The increased use 
of molecular techniques to characterize the microbial ecosystems have demonstrated their 
utility in identifying small, distinct populations of enterococci that would otherwise not 
have been isolated without a series of species-optimized isolation protocols (242).  In 
fact, enterococci have been estimated to account for only 7% of the microflora of poultry 
litter through the application of 16S rDNA sequence analysis (175).  Unfortunately, a 
snapshot of the microbial diversity of a given sample, while valuable, provides a limited 
amount of information compared with the questions that can be sated by the analysis of a 
collection of bacterial isolates.   
The second area of study focused on the susceptibility of the recovered 
enterococcal population to a number of antimicrobial agents.  This work demonstrated 
the magnitude of resistance to a number of antimicrobials that are used in clinical 
medicine or in agriculture.  Among the isolated enterococcal species, resistance was 
observed to multiple antimicrobials among a significant proportion of isolates.  The 
prevalence of resistance to production drugs was predictably higher among E. faecalis 
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and E. faecium from poultry production and processing environment across the 
geographic area of the Delmarva Peninsula.  The relative paucity of resistance among 
enterococci from this environment to clinical drugs that have been approved in veterinary 
medicine should be reassuring, however, the detection of any resistance in this 
environment is unsettling.  The fact that the enterococci from this work were not isolated 
with the addition of selective pressure from an incorporated antimicrobial suggests that 
an increase in resistance prevalence would be observed.  The presence of a reservoir of 
antimicrobial resistance, such as antibiotic-resistant enterococci evokes concern, given 
the renowned ability of enterococci to acquire genetic elements that confer resistance to 
antimicrobials and to spread those elements to other genera (287).   
Of significant relief to both opponents and advocates of antimicrobial use in food 
animal production was the absence of resistance to vancomycin.  This observation 
strengthens the argument that enterococcal resistance to vancomycin in the clinical 
environment is due to the use of vancomycin in that environment.  On the other hand, 
resistance to quinupristin-dalfopristin among isolates of E. faecium of food animal origin 
is widely prevalent, especially among poultry, which is reflected in this work.  An 
increased prevalence is of no surprise given the length of time that the analogue 
virginiamycin has been used in poultry production.  The high prevalence of this 
phenotype among E. faecium from poultry would suggest that the community is likely to 
already be seeded with resistant isolates (123).  Glycopeptide or streptogramin-resistant 
E. faecium from meat sources have been demonstrated to survive gastric passage and 
multiply, with subsequent isolation from feces up to two weeks following ingestion by 
healthy human volunteers (275).  Reports from German health agencies, however, 
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suggest that human carriage of Q-D-resistant E. faecium occurs at a rate of 14% (317) 
which is significantly higher than the estimates of 0 to 1% in the U.S. (186).   
The discrepancy in the between European and U.S. observations of the prevalence 
of resistance to this antimicrobial may be due to several factors.  One possibility is that 
the resistant E. faecium strains in Europe have also acquired virulence determinants that 
allow them to be better adapted to a human host, whereas adapted U.S. strains have 
prevented detectable colonization of the gut.  Another possibility is that the outpatient 
populations sampled between the two studies had significantly different eating habits and 
presumably different levels of exposure to resistant strains.  This suggestion has some 
credence, because diet has been shown to greatly impact the prevalence of resistant 
enterococci in the intestines of humans whose food consumption varies between 
carnivorous and vegetarian diets (260).  Differences in isolation methodology make the 
comparison of the two studies difficult and may have also affected the observed 
prevalence of comparative resistance between the two studies.  In particular, the choice of 
selective media, incubation temperature, and number of isolates may have prevented a 
better estimate of the true prevalence of QDREF in feces from healthy members of the 
community. 
Few studies have documented that Q-D resistance among vancomycin-resistant E. 
faecium isolates is a problem in the clinical setting, however if the lessons with VRE are 
not heeded with newer antimicrobials, streptogramin-resistant E. faecium may be poised 
to emerge as a significant nosocomial pathogen.  Increased usage of Q-D in the hospital 
setting to treat VREF would prompt the emergence of clones of streptogramin-resistant 
E. faecium and would only spur the increased use of vancomycin, in turn further 
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shortening the long-term efficacy of both drugs.  For these reasons, the U.S. medical 
community may be near the brink of losing another drug in their arsenal due to two risk 
factors: increase in community carriage rates from protracted use in agriculture and the 
standard overuse of antimicrobial agents in U.S. hospitals.  The results of this work 
establish a comparative baseline of resistance among Enterococcus spp. from poultry 
environments to many antimicrobials of use in human and veterinary medicine.  This 
information is vital for comparison in future studies that monitor the dynamics of 
resistance in or from this environment. 
The medical significance of antimicrobial resistance upon the virulence of 
enterococci is largely unknown.  Whereas increased mortality has been established 
among VREF compared with susceptible isolates in cases of similar severity (280), other 
studies have not confirmed these findings (108,168).  This variation may be due to 
differences in compensatory mechanisms among strains responsible for outbreaks that 
reduce the fitness cost of resistance to the bacterial host (60).  Given that some virulence 
and resistance mechanisms in enterococci have been demonstrated to be similarly 
regulated, the regulatory mechanisms may hold some promise as therapeutic targets 
(277).  Until demonstrated otherwise, the question will remain as to whether the 
acquisition of a resistant bacterium increases the severity of a patient’s illness or whether 
the severity of an illness predisposes a patient to the acquisition of a resistant bacterium. 
The third area of this study focused on the genetic background behind the 
observed resistance to macrolide, lincosamide, and streptogramin antimicrobials.  These 
three classes of antimicrobials are widely used in poultry production in the U.S. and 
present a unique situation with regard to antimicrobial resistance among enterococci, i.e., 
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the use of any one of these drugs can select for resistance to the others in animal 
agriculture.  This work is the first to examine in a single study all known MLS resistance 
mechanisms that have been described to date.  This information is critical to begin to 
evaluate the potential risk that the use of related antimicrobials in animal agriculture 
poses to the treatment of disease among the human population.  Among isolates 
phenotypically resistant to macrolide, lincosamide, or streptogramin antimicrobials, it 
was demonstrated in this work that a significant proportion possess uncharacterized 
mechanisms of resistance.  As previously discussed, the absence of these resistance 
elements has been previously described among isolates of E. faecium.  These results are 
at variance with the observations from Denmark, in which the presence of the 
acetyltransferases vat(D) and vat(E) accounted for most Q-D resistance in poultry, but is 
similar to the predominance of observations among isolates with unknown mechanisms 
from pigs (138).  Thus, this work should be seen in the context of the urgent need for 
science-based risk assessments, focusing on the relative risks concerning use of 
antimicrobials in animal husbandry in the U.S.   
Based on the current understanding of how MLS antimicrobials interact with the 
A2058 residue of 23S rRNA of the 50S subunit as described earlier, it is likely that the 
mechanism(s) that confer resistance among the 48% of isolates that had a ML resistance 
phenotype in this work do so by target site modification, most likely due to methylation 
of that site by an unknown mechanism.  The comparatively high prevalence of 
lincosamide resistance may be due to the activity of an undetermined efflux pump or 
major facilitator protein that has specificity for such moieties.  For example, Lmr(A) is an 
efflux pump that confers resistance to lincosamide antimicrobials, but has only been 
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isolated from Streptomyces lincolnensis (334).  Major facilitator mechanisms like Msr(A) 
demonstrate macrolide specificity and confers resistance to 14-member macrolides and 
streptogramin B components, but not lincosamide and 16-member macrolides among S. 
epidermidis (245).  Given this resistance profile, the presence of msr(A) among isolates 
in this work is possible in 3% (4/127) of E. faecium, assuming that the transporter 
behaves similarly among Enterococcus spp.  Alternatively, lincosamide resistance may 
be due to inactivation of the antimicrobial, possibly due to the activity of a 
nucleotidyltransferase.  Resistance to streptogramin antimicrobials may be similarly 
mediated by efflux or inactivation mechanisms.  The results of prior surveys suggest that 
resistance to streptogramin A components is unlikely due to the activity of 
acetyltransferases that are common among Staphylococcus spp., but cannot be excluded 
as a possibility (267,273).  Unpublished reports have suggested that these alternative 
mechanisms of streptogramin resistance are mobile in nature (319). 
Mutation of the target site of MLS antimicrobials may be a possible mechanism 
of resistance among these isolates.  Isolates that possess this or closely related mutations 
may not be phenotypically resistant to MLS antimicrobials until induced.  It remains 
entirely possible that a number of E. faecium isolates from this work may possess this 
mutation and remain inducibly resistant, however this phenotype quickly becomes 
constitutive after exposure to inducing antimicrobials.  The presumed frequency of use of 
inducing antimicrobials in the U.S. poultry industry would likely be sufficient to facilitate 
this switch.  Because only 17% of E. faecium isolates in this study possessed a MLS 
resistance phenotype and were widely distributed across the sampling area, it is unlikely 
that this is a common trait.   
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This work also demonstrated the utility of ribotyping in helping to distinguish 
genetically similar clusters of E. faecium.  Whereas the method is not as robust as pulsed-
field gel electrophoresis (PFGE), it did successfully illustrate the diversity of recovered 
E. faecium isolates with relation to their phenotypic resistance to MLS antimicrobials.  
Ribotype analysis also illustrated the predominance of a few related ribotypes across the 
entire geographic region sampled.  This would suggest that these bacterial populations 
are common among farms because theses populations of E. faecium are either naturally 
predominant in poultry or that the strains have been disseminated widely across this 
region through the operation of the widely integrated poultry industry.  Ribotyping could 
be very useful as a rapid screening method for investigating genetic relationships among 
isolates from diverse environments and for identifying strains of particular epidemiologic 
relevance.  Databases of important ribotypes could be constructed to allow remote 
identification and tracking of these clones longitudinally and on a worldwide scale. 
Future work should continue to investigate the mechanisms behind the large 
degree of uncharacterized resistance to MLS antimicrobials.  The degree to which these 
mechanisms exist among resistant isolates from community and clinical sources remains 
an important question.  These mechanisms may very well persist in streptogramin-
resistant isolates that also possess acetyltransferases due to vat(D) or vat(E) genes.  Given 
the nature of the spread of antimicrobial resistance among gram-positive organisms that 
are widely distributed in the environment, the presence of multiple mechanisms may very 
well pose multiple threats to the long-term efficacy of streptogramin antimicrobials.  The 
potential spread of these mechanisms from poultry or other production environments 
through consumption of contaminated meat may establish a reservoir of resistance in the 
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community.  Whereas this resistant population or resistance elements may not rise to a 
measurable level, the stage may be set for the emergence of resistance following the 
application of selective pressure.  This would be especially important if the trends of Q-D 
usage increase due to the diminished effectiveness of alternative therapeutics.   
Molecular technologies to monitor antimicrobial resistance will be critical tools to 
monitor the epidemiology of specific resistance elements.  Microelectronic chip 
technology has proved to be a promising venue for such applications and has been shown 
to possess advantages over traditional procedures in terms of time and cost savings in the 
identification of bacteria in addition to the characterization of molecular resistance 
determinants (320).  This technology can also be adapted for use in metagenomics to 
establish the reservoirs of resistance genes among the fecal bacterial microflora that have 
heretofore been marginalized by either their low prevalence or virulence in animal or 
human hosts.  This knowledge could conceivably be utilized to model and direct 
intervention strategies against these carrier populations with the intent to minimize the 
development of an unfavorable population dynamic that would favor the emergence of 
resistance. 
Experiences of other countries yield important information about what changes 
might be expected with a restricted use of antibiotics.  Models for monitoring the effect 
of the withdrawal of antimicrobials used as growth promotants strongly link the ban of 
these drugs to the decrease in prevalence of erythromycin and virginiamycin resistance 
among E. faecium isolates from poultry meat in Denmark, as well as Germany (87,156).  
Despite the optimism that the removal of production drugs like avoparcin from animal 
agriculture will eradicate the presence of resistant isolates in animals, animal products, 
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and the healthy human population (298), observations of a decreased but stable 
prevalence of resistant isolates among bacterial populations suggests that resistance may 
persist, albeit in lower numbers (7,250).  Among isolates of E. faecium from Danish 
broilers, the prevalence of resistance has moderated with stabilization of resistance at 
13% for erythromycin and 34% for virginiamycin (7,17).  Vancomycin resistance was 
observed to quickly decrease from 73% among broiler isolates before the avoparcin ban 
to 43% in the first year without the use of avoparcin.  The prevalence of VREF from 
these environments has apparently stabilized at 6%. 
Amid a storm of public controversy concerning the use of antimicrobials in 
agriculture, the EU in 1999 banned the use of all antimicrobials employed as growth 
promotants.  Whereas a consistent picture of the effect of this ban has yet to emerge, 
there is evidence to suggest that food animal welfare has suffered.  In pigs, increased 
morbidity and mortality attributable to enteric infections have been increasingly frequent 
(42).  The result of the increased frequency of diarrhea as well as chronic infections due 
to Lawsonia intracellularis in Denmark and Spain has been a decrease in weight gain and 
increased mortality.  Necrotic enteritis due to clostridial infections have increased among 
poultry from Denmark and France.  In both environments, the use of therapeutic 
antimicrobials to treat food animals has substantially increased (200,228).  A pilot study 
of organic farm practices in Denmark suggest that an increase in the carriage rate of 
human pathogens among food animals may be an unintended consequence of removing 
antimicrobials from food animal production (125).  Recent reports from Denmark have 
observed the opposite response with a decrease in Campylobacter and Salmonella spp. in 
poultry and pork products (91).  The potential for increased bacterial contamination of 
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meat products by human pathogens is also of concern in the processing of the food 
animal, owing largely to a more diverse range of sizes and weights of incoming animals 
for slaughter.  This can realistically be expected to occur at the processing facility due to 
the high speed and largely automated sequence of animal processing and the increased 
heterogeneity of food animals raised without the use of antimicrobial agents to 
prophylactically treat animal disease.  Thus, a balance between the interests of the 
management of resistant human food-borne infections and the frequency of infections 
may be required. 
 Improvements in farm management practices are increasingly important areas of 
research in order to compensate for the potential removal of antimicrobials to control 
food-animal infections (74).  Improvements in sanitation, pest control, and litter 
management would help to reduce the exposure of food animals to pathogens.  
Enhancements such as the use and proper maintenance of watering and air handling 
systems and improved temperature control are also important.  Development of methods 
to augment the immune response of food animals are also very viable means of 
enhancing the resistance of food animals to disease.  This is likely to come in the form of 
vaccines and improved vaccine delivery vehicles as well as modulation of the immune 
response by the application of specific antibodies and augmenting cytokine response of 
food animals.  The most robust area of research is currently in the modification of 
nutritional regimens and additives.  The most active areas of research include the addition 
of enzymes to assist in feed digestion and organic acids to control intestinal pathogens, as 
well as other means of supplementation or modification of feedstuffs.  Other strategies 
that have yet to see widespread acceptance and use include supplementation with 
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probiotic and bacteriophage preparations.  It is expected that a combination of efforts 
would be required by food animal production industries to compensate for the losses of 
weight gain and feed efficiency that antimicrobials currently provide. 
 Despite the frequency of antimicrobial resistance observed among enterococci 
from this work, the burden of managing the problem should not fall solely on the 
shoulders of agricultural industry.  Significant improvements in the prudent use of 
antimicrobials in the clinical environments can and should be made.  These include the 
proper prescription of antimicrobial therapy to treat a bacterial infection, improved 
sanitation in medical facilities, and the proper education of consumers of medical 
services.  This is especially relevant with the control of VRE in hospital settings, as the 
use of vancomycin is a strong predictor for the emergence of resistance (32,147,172,246). 
A rather neglected area of research is the downstream effects of antimicrobial 
usage in animal agriculture as well as human medicine.  Many antimicrobials used in the 
food animal production environment are poorly absorbed in the gut.  This property makes 
them excellent additives to animal feed for the sake of avoiding detectable tissue 
residues, but this also means that a significant portion of the active agent is excreted into 
the environment with as much as 75% of antibiotics administered in feedlot animals 
found unaltered in feces (85).  Given the variability in production practices, specifically 
litter management, the concentration of antimicrobials in litter from successive flocks 
being fed supplemented feed rations may accumulate to a significant level (166).  
Virginiamycin, in particular, possesses a long biodegradation half-life in different soils 
(309).  Use of litter as fertilizer for produce could potentially create selective pressure 
that might affect the bacterial flora of the product.  Indeed, the influence of antimicrobial 
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usage in integrated fish farming has been significant, with the increased prevalence of 
species from broilers and their resistance profiles found among overseas integrated fish 
operations (226,227).  Alternatively, the antimicrobials, bacteria, and resistance 
determinants may be transported from the surface application of litter and find their way 
into various environments through groundwater (49,166).  The comparison of results 
from areas proximate to poultry production environments to those established in this 
work would be of great interest. 
Rising levels of resistance to multiple antimicrobials dictates the frequent and 
close monitoring of resistance in bacterial pathogens in both clinical and agricultural 
environments in the U.S. and abroad.  Without this measure of surveillance, the 
management of this problem on a piecemeal basis could very well result in further 
waning of the effectiveness of antimicrobials and additionally lead to the reduction of the 
numbers of antimicrobials available to treat human infections.  Additionally, surveillance 
is valuable to closely monitor the response of microbial populations to drugs that recently 
have or are soon to be introduced into clinical medicine (41,153,234) as well as the 
effectiveness of new antimicrobial regimens (276).  The increase in public concern has 
led to the ban of growth promoting antimicrobials in the EU based on the perceived risk 
rather than clear scientific evidence (230). Failure to exercise continuing, efficient and 
sound scientific judgment in search of a means to reduce antibiotic resistance could, 
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